On this page
Quick Reference
Overview and Recommendations
Background
- •Type 1 diabetes mellitus (T1DM), absolute insulin deficiency from autoimmune beta-cell destruction, affects approximately 1.45 million people in the United States, with a global incidence rising 3-4% per year, a pace too rapid for genetic drift alone.
- •The disease follows a predictable staging paradigm: Stage 1 (≥2 islet autoantibodies, normoglycemia), Stage 2 (autoantibodies plus dysglycemia), and Stage 3 (symptomatic hyperglycemia). Progression from Stage 1 to clinical diabetes occurs in >70% of individuals over 5 years.
- •The autoimmune attack targets well-characterized beta-cell antigens: GAD65 (glutamic acid decarboxylase), IA-2 (insulinoma-associated protein 2), ZnT8 (zinc transporter 8), and insulin. CD8+ cytotoxic T-cells mediate destruction via perforin/granzyme and Fas-FasL pathways.
- •Genetic susceptibility is dominated by HLA class II haplotypes DR3-DQ2 and DR4-DQ8 (OR >20 for heterozygotes), with additional risk from non-HLA loci including PTPN22, INS, CTLA4, and IL2RA. Environmental triggers, most consistently enteroviral infection, initiate or accelerate autoimmunity in genetically predisposed individuals.
Evaluation
- •Suspect T1DM in any patient with polyuria, polydipsia, unintentional weight loss (5-10% over weeks), fatigue, blurred vision, or new-onset nocturnal enuresis in children.
- •Ask about the duration of symptoms, classic T1DM progresses over 2-6 weeks in children and adolescents; adults may have a more insidious course over months.
- •Ask about family history of T1DM (RR 15 for first-degree relatives), other autoimmune diseases (thyroid, celiac, Addison's), and recent viral illness.
- •Examine for signs of dehydration (dry mucous membranes, reduced skin turgor, tachycardia), Kussmaul respirations, acetone breath, and altered mental status indicating DKA.
- •Order STAT fingerstick blood glucose and urine or serum ketones (beta-hydroxybutyrate) in any symptomatic patient.
- •Confirm diabetes with fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%.
- •Assess for DKA using the triad: glucose >250 mg/dL, venous pH <7.3, serum bicarbonate <15 mEq/L, and positive ketones.
- •Measure C-peptide (fasting or stimulated) to distinguish T1DM from type 2 diabetes: fasting C-peptide <0.2 nmol/L (<0.6 ng/mL) confirms absolute insulin deficiency.
- •Order islet autoantibody panel (GADA, IA-2A, ZnT8A), ≥1 positive confirms autoimmune etiology; panel sensitivity is 85-90% at diagnosis.
- •If autoantibodies are negative, consider genetic testing for monogenic diabetes (WFS1, INS, GCK, HNF1A, HNF4A), especially in young children or those with family history.
- •Screen for associated autoimmune diseases at diagnosis: TSH and TPO antibodies (autoimmune thyroid disease in 15-30% of T1DM), tissue transglutaminase IgA (tTG-IgA) for celiac disease.
- •In a patient with DKA, assess severity by venous pH (mild pH 7.25-7.30, moderate pH 7.00-7.24, severe pH <7.00) and triage to appropriate level of care.
- •Use an algorithm for antibody-negative cases: if C-peptide low, consider idiopathic T1DM or monogenic diabetes; if C-peptide normal/high, consider type 2 diabetes or MODY.
Management
- •Initiate insulin therapy immediately once T1DM is confirmed. Start basal-bolus regimen at total daily dose (TDD) of 0.5-1.0 U/kg/day.
- •Administer 50% of TDD as basal insulin, insulin degludec (0.2-0.4 U/kg once daily), glargine U100 (0.2-0.4 U/kg once daily), or glargine U300 (0.3-0.5 U/kg once daily). Degludec reduces nocturnal hypoglycemia vs glargine (rate ratio 0.75, 95% CI 0.59-0.96).
- •Administer 50% of TDD as prandial rapid-acting analogue (lispro, aspart, glulisine) at 0.05-0.15 U/kg per meal, adjusted for carbohydrate content and premeal glucose.
- •For DKA: fluid resuscitation with 0.9% normal saline 15-20 mL/kg over first hour (1 L in adults), then 250-500 mL/h. Replace half the deficit over 8 hours.
- •For DKA: after fluids, give regular insulin 0.1 U/kg IV bolus, then 0.1 U/kg/h continuous IV infusion. Do not start insulin if K+ <3.3 mEq/L, replete potassium first.
- •When blood glucose falls to 250 mg/dL, add 5% dextrose to IV fluids and reduce insulin to 0.05-0.1 U/kg/h to maintain glucose 150-200 mg/dL until acidosis resolves.
- •Replace potassium when serum K+ <5.3 mEq/L: add 20-30 mEq potassium chloride or phosphate per liter IV fluid, target K+ 4-5 mEq/L. Monitor every 2 hours.
- •Reserve bicarbonate for pH <6.9: give 50-100 mEq NaHCO₃ in 200 mL sterile water over 30-60 minutes with ECG monitoring. Do not use routinely.
- •Transition from IV to subcutaneous insulin only after DKA resolves (anion gap <12 mEq/L, pH >7.3). Overlap IV and SC insulin by 1-2 hours.
- •Titrate all patients to HbA1c <7.0% (<53 mmol/mol) for most nonpregnant adults; target <7.5% for children and adolescents to balance hypoglycemia risk.
- •Prescribe continuous glucose monitoring (CGM) for all patients with T1DM, reduces severe hypoglycemia by 40-50% and improves HbA1c by 0.3-0.5% in adults ≥25 years.
- •Advanced hybrid closed-loop systems (MiniMed 780G, Tandem Control-IQ) are recommended as preferred therapy, achieve time-in-range >70% with reduced hypoglycemia.
- •For severe hypoglycemia (unconscious or unable to swallow): give glucagon 1 mg IM or intranasal 3 mg, or IV dextrose 50% 25 g. Recheck in 15 minutes.
- •For conscious hypoglycemia (<70 mg/dL): administer 15-20 g oral glucose (4 oz juice, 3-4 glucose tablets); repeat in 15 minutes if still <70 mg/dL.
- •Anticoagulate with statins in all patients aged ≥40 years, or younger with LDL ≥100 mg/dL, hypertension, smoking, or family history of premature CVD. Target LDL <70 mg/dL.
- •Add ACE inhibitor or ARB when urinary albumin-to-creatinine ratio (UACR) >30 mg/g, regardless of blood pressure, to slow nephropathy progression.
- •Do not use SGLT2 inhibitors as routine adjunct, 3.5-fold increased DKA risk (NNH = 28) and FDA boxed warning; consider only in clinical trials.
- •Do not use non-dihydropyridine CCBs (diltiazem, verapamil), they exacerbate heart failure in diabetic cardiomyopathy.
- •Do not omit basal insulin during illness or fasting, this is the most common precipitant of DKA. Increase insulin by 20-50% during intercurrent illness.
Board Review — High Yield
- •DCCT/EDIC study, intensive insulin therapy (HbA1c ~7%) reduces retinopathy by 76%, nephropathy by 54%, CVD by 42%; legacy effect persists for decades despite later HbA1c convergence.
- •C-peptide <0.2 nmol/L, distinguishes T1DM (absolute deficiency) from T2DM with high specificity; stimulated C-peptide <0.6 nmol/L confirms severe beta-cell loss.
- •GADA, IA-2A, ZnT8A, ≥1 positive confirms autoimmune etiology; ZnT8A useful in antibody-negative cases and may signal concurrent autoimmune thyroiditis.
- •HLA DR3-DQ2 and DR4-DQ8, strongest genetic risk (OR >20 for heterozygotes); non-HLA loci (PTPN22, INS, CTLA4) contribute modest additive risk.
- •DKA triad, glucose >250 mg/dL, pH <7.3, bicarbonate <15 mEq/L with ketones; treatment: NS 15-20 mL/kg, IV insulin 0.1 U/kg bolus + 0.1 U/kg/h, K+ replacement.
- •DO NOT use bicarbonate for DKA unless pH <6.9, no outcome benefit, may worsen hypokalemia and cerebral edema.
- •Advanced hybrid closed-loop (AHCL), preferred therapy; MiniMed 780G and Tandem Control-IQ achieve TIR >70% with fewer hypoglycemic events vs MDI.
- •SGLT2i contraindicated in T1DM, 3.5-fold DKA risk (NNH 28); avoid outside clinical trials despite HbA1c reduction of 0.37%.
- •Autoimmune polyglandular syndrome type 2, Addison disease + T1DM or thyroid disease; screen with TSH, TPO antibodies, tTG-IgA at diagnosis; annual TSH thereafter.
- •Teplizumab (anti-CD3), first FDA-approved disease-modifying therapy; delays progression from Stage 2 to Stage 3 T1DM by ~2 years in at-risk individuals.
Deep Dive — Evidence Details
Definition, Classification and Axis Nomenclature
- ▸T1D is an autoimmune diabetes phenotype associated with loss of β-cell secretory capacity and insulin dependence. [245][255][257]
- ▸Classification is multidimensional: immune etiology, age and tempo phenotype, residual β-cell reserve, disease stage, and complication/comorbidity status. [245][251][254][255]
- ▸Classical adult-onset autoimmune diabetes and LADA belong to the broader autoimmune spectrum but should remain separately identified when clinically applicable. [245]
- ▸Diabetes-associated autoantibodies, including GAD-related and insulin-directed antibodies, support etiologic classification but should be interpreted with clinical and laboratory data. [12][251]
- ▸ICD-10 code E10 is an administrative designation and should not be treated as a complete biological definition of T1D. [257]
Definition
Type 1 diabetes mellitus (T1DM), also termed type 1 diabetes (T1D), is an autoimmune diabetes phenotype characterized by loss of pancreatic β-cell secretory capacity and clinically important insulin dependence. The supplied literature explicitly describes T1D as autoimmune and identifies impaired or residual β-cell secretion as a central pathophysiological feature. [245][255][257] The term should be reserved for diabetes classified as type 1 rather than used as a synonym for all insulin-treated diabetes, because exogenous insulin use can also occur in other diabetes phenotypes. [245][258]
T1D is biologically heterogeneous. Differences have been reported in age at onset, rate of disease progression, immune-cell profiles, residual β-cell function, and complication risk, supporting the use of disease “endotypes” or biologically distinct subgroups rather than assuming a uniform course. [245][255] Classical adult-onset autoimmune diabetes and latent autoimmune diabetes in adults (LADA) may be grouped within the broader autoimmune type 1 spectrum, although the supplied evidence presents LADA as a related phenotype that may be analyzed separately. [245]
Classification axes
Etiologic or immune axis. The principal classification distinction is autoimmune type 1 diabetes versus other diabetes phenotypes. Diabetes-associated autoantibody profiles, including antibodies directed against glutamic acid decarboxylase and insulin, have been evaluated as classification variables, and combined antibody, clinical, and routine laboratory models have been developed to distinguish T1D from other forms of diabetes. [12]B3b[251] GAD65-related autoimmunity may also coexist with T1D in broader autoimmune syndromes, including autoimmune polyglandular syndrome type III, which is defined in the cited study by autoimmune thyroiditis plus another autoimmune disorder other than Addison disease. [249]C
Phenotypic axis. The clinical phenotype may be described by age and tempo of onset, including childhood or adolescent presentation, classical adult-onset autoimmune diabetes, and LADA. [245][246][254] Age alone does not establish the classification, because adult-onset autoimmune diabetes and LADA are specifically included among the phenotypes assessed in comparative β-cell studies. [245] Pediatric T1D commonly enters clinical attention through diabetic ketoacidosis (DKA), which is described as a life-threatening complication and may be accompanied by hypovolemia, hyperchloremia, and acute kidney injury. [252]
β-cell reserve axis. Residual endogenous insulin secretion is a useful biological axis. Fasting and glucagon-stimulated C-peptide measurements have been used at diagnosis to quantify β-cell secretory reserve across T1D, LADA, and type 2 diabetes, while longer-term studies have examined associations between baseline reserve, glycaemic control, and subsequent outcomes. [245] Lower or declining reserve should be interpreted as a biological descriptor of disease severity or progression, not as a stand-alone replacement for etiologic classification. [245]
Disease-stage axis. The supplied studies support a distinction between risk or preclinical prediction, newly diagnosed disease, and established T1D. Transcriptomic models have attempted to predict childhood diabetes up to 46 months before clinical diagnosis, whereas other studies evaluate patients at diagnosis or after at least 1 year of disease duration. [254][246] This evidence supports stage-based nomenclature but does not establish a universally validated staging system for T1D itself. [254][251]
Complication and phenotype-modifier axis. Once T1D is established, additional descriptors may specify microvascular, macrovascular, renal, ocular, neurologic, reproductive, or autoimmune comorbidity status. Diabetic macular edema and retinal vascular abnormalities have been studied across stages of diabetic retinopathy in T1D. [8]A1a[248]C Microalbuminuria is used as an early marker of diabetic kidney disease, and serum uric acid has been investigated as an associated marker in pediatric T1D. [246] Central adiposity, particularly a waist-to-height ratio of ≥0.5 or ≥0.6, has been associated with cardiovascular outcomes in adults with T1D. [10]B2b Longstanding T1D may also be characterized by macrovascular complications and distinct peripheral immune-cell profiles. [253][255] Other relevant modifiers include diabetic peripheral neuropathy, androgen-excess disorders in premenopausal women, autoimmune thyroid disease, celiac disease, and autoimmune neurologic syndromes. [12]B3b[249]C[256][258]
Axis nomenclature and terminology
A practical nomenclature should therefore state the disease label followed, where relevant, by the dominant axes: T1D—etiology; age/tempo phenotype; β-cell reserve; disease stage; and complication or comorbidity status. For example, “adult-onset autoimmune T1D with preserved residual C-peptide” is more informative than “adult diabetes,” while “pediatric T1D presenting with DKA and acute kidney injury” identifies phenotype and acute stage. [245][252] “LADA” should be retained when the clinical context specifically identifies latent autoimmune diabetes in adulthood, rather than automatically relabelling every adult autoimmune presentation as classical T1D. [245]
Administrative nomenclature should be distinguished from biological nomenclature. In ICD-10-based hospital datasets, T1DM is represented by code E10, but coding accuracy requires validation against diagnostic criteria because registry codes may not perfectly reflect clinical classification. [257] Conversely, the absence of an association between in-vitro fertilization conception and offspring T1D risk does not define a diabetes subtype and should not be incorporated into the classification axes. [11]B3b Similarly, maternal T1DM and offspring atopic dermatitis, chronic pancreatitis associations, and other epidemiologic relationships are contextual findings rather than diagnostic criteria for T1D. [9]B2b[250]
No single supplied reference establishes a universally accepted classification system encompassing all of these axes. The proposed retinal-detachment staging system concerns tractional retinal detachment in T1D, not classification of diabetes itself. [244] Accordingly, etiologic, phenotypic, biological, staging, and complication descriptors should be reported separately and should not be conflated with one another. [244][245][251][255][257]
| Axis | Suggested descriptors | Evidence-supported examples |
|---|---|---|
| Etiology | Autoimmune type 1; other diabetes phenotype | Diabetes autoantibody profile; GAD65-related autoimmunity [12]B3b[249]C[251] |
| Clinical phenotype | Childhood/adolescent onset; adult-onset autoimmune diabetes; LADA | Classical adult-onset autoimmune T1D and LADA [245] |
| β-cell reserve | Preserved, reduced, or declining endogenous secretion | Fasting or glucagon-stimulated C-peptide [245] |
| Stage | At risk/preclinical; newly diagnosed; established | Prediction up to 46 months before diagnosis; diagnosis or ≥1 year duration [246][254] |
| Acute or chronic modifiers | DKA, kidney, retinal, cardiovascular, neurologic, reproductive, or autoimmune status | DKA with AKI; macular edema; cardiovascular risk; neuropathy; autoimmune comorbidity [8]A1a[10]B2b[12]B3b[246][248]C[249]C[252][253][256][258] |
| Administrative | ICD-10 E10 | Coding requires clinical validation [257] |
Axis Physiology, Pathophysiology and Biochemical Signature
- ▸T1DM is an autoimmune β-cell destructive disorder with variable residual C-peptide reserve and heterogeneous inflammatory states [245][264][266].
- ▸Newly diagnosed T1DM shows NF-κB, EGFR, MAPK, hypoxia, and TNF-centered immune signatures in single-cell analyses [264].
- ▸Adjunctive GLP-1RAs provide modest HbA1c improvement of approximately **0.56%**, increase time in range, and reduce insulin requirements [40].
- ▸Pooled GLP-1RA evidence found neutral overall hypoglycaemia risk (**RR 1.01**) and no significant increase in serious adverse events (**RR 0.89**) [39].
- ▸SGLT2-associated DKA remains a major safety concern in insulin-deficient diabetes [40].
- ▸S1P-related trafficking, lipidomic abnormalities, gut–brain signaling, and anti-ACE2 autoantibodies are investigational signatures rather than validated diagnostic panels [259][260][262][266].
Overview of the axis
Type 1 diabetes mellitus (T1DM) is characterized in the supplied evidence as an autoimmune disease involving pancreatic β-cell destruction and clinically important loss of endogenous insulin secretory capacity [264][266]C. The resulting biochemical phenotype is not defined solely by hyperglycaemia: it also includes measurable impairment of β-cell reserve, altered insulin requirements, changes in body composition, and—particularly when insulin deficiency is intensified—risk of diabetic ketoacidosis (DKA) [245][31]A1a[40]A1a.
β-cell failure and insulin-secretory reserve
Fasting and glucagon-stimulated C-peptide are practical biochemical measures of residual β-cell secretory function [245]. In a prospective cohort of 393 adults with newly diagnosed diabetes, baseline C-peptide testing was used to compare classical adult-onset autoimmune diabetes, latent autoimmune diabetes in adults (LADA), and type 2 diabetes; 89 participants were reassessed after approximately seven years [245]. The study supports the concept that diabetes phenotypes differ in residual β-cell reserve and longitudinal secretory trajectories, although the supplied abstract does not provide the numerical C-peptide results or permit a precise threshold for preserved function [245].
Single-cell immune profiling further indicates that autoimmune diabetes is heterogeneous rather than immunologically uniform [264]. In more than 400,000 peripheral blood mononuclear cells from individuals with LADA, newly diagnosed T1DM, and healthy controls, overall immune-cell composition was comparable, whereas qualitative pathway differences distinguished the groups [264]. Newly diagnosed T1DM showed activation of NF-κB, EGFR, MAPK, and hypoxia-related pathways, with TNF-centered intercellular communication; LADA was described as a more indolent inflammatory state on a shared autoimmune spectrum [264].
Metabolic and hormonal physiology
Insulin therapy remains the physiological replacement for deficient endogenous insulin, while adjunctive therapies modify selected components of the metabolic axis rather than correcting autoimmune β-cell loss [40]A1a. Across 90 studies, GLP-1 receptor agonists (GLP-1RAs) produced a modest reduction in glycated haemoglobin of approximately 0.56 percentage points, increased time in range, and reduced total and basal daily insulin requirements in T1DM [40]A1a. A separate meta-analysis of randomized trials likewise found cardiometabolic effects of GLP-1RAs in T1DM, although the supplied abstract does not report the pooled numerical estimates [43]A1a.
The weight-loss phenotype of GLP-1RAs and sodium-glucose cotransporter-2 inhibitors (SGLT2is) is relevant to the biochemical signature because changes in body weight may include lean tissue as well as fat mass [31]A1a. The systematic review included five T1DM studies, but the supplied abstract does not provide a T1DM-specific pooled estimate for lean body mass; therefore, loss of lean mass should not be assumed to be uniform across agents or patients [31]A1a.
GLP-1RAs may improve glycaemia and insulin requirements, but gastrointestinal intolerance and ketosis-related safety concerns remain clinically relevant in insulin-deficient patients [39]A1a[40]A1a. Updated pooled evidence found no significant increase in overall hypoglycaemia, with a risk ratio of 1.01, and no significant increase in severe hypoglycaemia, with a reported risk ratio of 0.74, although certainty for severe hypoglycaemia was low [39]A1a. Serious adverse events were not increased, with a risk ratio of 0.89 and moderate certainty [39]A1a. SGLT2is require particular caution because adjunctive-therapy reviews identify DKA as a central safety concern [40]A1a.
Glucagon is an important counter-regulatory component of glucose physiology, but the supplied volagidemab study was performed in healthy Chinese and US participants rather than people with T1DM [269]C. It demonstrated dose-dependent pharmacokinetics and modeled the relationship between plasma glucagon concentrations and fasting plasma glucose after glucagon-receptor antagonism; these findings provide pharmacological physiology, not evidence for routine glucagon-receptor blockade in T1DM [269]C.
Immune, vascular, intestinal, and neural signatures
The sphingosine-1-phosphate (S1P) pathway is being investigated as a potential immunoregulatory signature because it controls lymphocyte trafficking [260]. An integrated study measured total serum S1P, HDL-bound S1P, and apolipoprotein M, and combined these measurements with single-cell transcriptomics of colonic tissue in T1DM and mouse models at pre-diabetic and established disease stages [260]. The supplied abstract confirms pathway investigation but does not provide the direction or magnitude of each biomarker change [260].
Gut–brain signaling and microbial metabolites are proposed research domains in T1DM-associated obesity, but current evidence in the supplied letter is hypothesis-generating rather than causal [259]. The authors call for gnotobiotic models, targeted metabolomics, and mechanistic studies to distinguish correlation from causation and to identify specific microbial metabolites [259].
Lipid metabolism may also contribute to diabetes-related neurological complications [262]C. In a pilot study of 36 T1DM participants without mild cognitive impairment, 33 with mild cognitive impairment, and 32 healthy controls, serum lipidomics were integrated with mouse hippocampal analyses to identify lipidomic patterns associated with cognitive impairment [262]C. The supplied abstract does not specify individual lipid species or diagnostic cut-offs, so these findings should be regarded as exploratory rather than an established biochemical panel [262]C. Young adults with T1DM also demonstrated early and subtle differences in resting-state brain activity using fALFF, regional homogeneity, and homotopic-connectivity measures; these neuroimaging findings are functional correlates, not biochemical diagnostic criteria [263].
Clinical biochemical expression
Polyuria reflects severe osmotic disturbance and is frequently observed in DKA or new-onset T1DM; a systematic review of pediatric cases identified 19 children with polyuria and DKA and five with new-onset T1DM without DKA among the reviewed patients [41]C4. DKA-associated acute kidney injury was also reported in this case-based literature, although the supplied abstract does not provide a definitive prevalence estimate [41]C4. Post-COVID-19 T1DM has additionally been investigated through anti-ACE2 autoantibodies, based on the presence of ACE2 in pancreatic islets and proposed mechanisms including molecular mimicry, inflammation, and direct β-cell injury; the study included 35 post-COVID-19 patients with new-onset T1DM and 30 recovered controls [266]C. These findings remain associative and do not establish ACE2 autoantibodies as a validated diagnostic signature [266]C.
Digital interventions may improve adherence to insulin administration and glucose monitoring and may reduce HbA1c, but their effects concern management behavior rather than the underlying autoimmune axis [42]B2a. A mobile-app study similarly evaluated HbA1c, glucose-trend visualization, engagement, and user experience in 148 adults with T1DM, but does not alter the biological definition of T1DM [267]. Registry data in adults aged ≥60 years indicate persistent opportunities to improve risk-reduction therapy and treatment-target attainment, emphasizing that the biochemical phenotype and its consequences remain clinically relevant throughout older adulthood [268].
| Domain | Observed or investigated signature | Interpretation |
|---|---|---|
| β-cell reserve | Fasting and glucagon-stimulated C-peptide | Measures residual endogenous insulin secretion; phenotype-specific trajectories are under study [245] |
| Glycaemic control | HbA1c and time in range | Improved modestly with adjunctive GLP-1RA therapy [40]A1a |
| Insulin physiology | Total and basal daily insulin requirements | Reduced in GLP-1RA adjunctive-therapy studies [40]A1a |
| Immune biology | NF-κB, EGFR, MAPK, hypoxia, and TNF-centered communication | Qualitative inflammatory signature of newly diagnosed T1DM [264] |
| Lipid and vascular biology | Total S1P, HDL-bound S1P, ApoM, and lipidomic profiles | Investigational systemic and complication-associated biomarkers [260][262]C |
| Acute metabolic decompensation | Polyuria and DKA-associated kidney injury | Clinical expression of severe metabolic disturbance, especially in pediatric presentations [41]C4 |
Epidemiology, Etiology and Risk Factors
- ▸Incidence rising 3-4% per year; highest in Finland, lowest in China.
- ▸Genetic risk: HLA-DR3/4-DQ2/8 heterozygosity OR >20; environmental triggers include enterovirus, caesarean section, vitamin D insufficiency.
Global incidence rising 3-4% per year [2]A1a. Highest in Finland (64.2 per 100,000 person-years in children <15), lowest in China and Venezuela (<1 per 100,000) [2]A1a[76]D5. Global average ~15 per 100,000 children. Prevalence in Europe/North America 0.2-0.5%; 1.45 million in U.S. (2020) [2]A1a[76]D5. Age peaks: 4-6 years and 10-14 years [76]D5. Before puberty, equal sex incidence; after 15, male predominance (1.5:1) [58]B2a[76]D5. Girls have higher HbA1c and more DKA (diabulimia) [58]B2a[74]D5[84]B2b. Incidence in children <5 doubled since 1990s [2]A1a[76]D5. Etiology: autoimmune (>95% childhood-onset) [76]D5; iatrogenic (checkpoint inhibitor-induced, 0.2-0.9% of ICI recipients, median onset 3-4 weeks, >50% present with DKA) [20]C4[66]B2b; genetic (monogenic forms like MODY, 1-2% of all diabetes) [64]D5; other (pancreatitis, pancreatectomy, cystic fibrosis-related diabetes) [64]D5[81]A1a. Risk factors: genetic (HLA-DR3-DQ2/DR4-DQ8 OR 5-10, both haplotypes OR >20) [76]D5; non-HLA genes (INS, PTPN22, CTLA4, IL2RA OR 1.1-1.5) [76]D5. Environmental: caesarean section (OR 1.23) [60]B3a, early term birth (RR 1.33) [50]B2a, enteroviral infection (OR 2-3) [76]D5, vitamin D insufficiency (OR 2-4) [68]B3b, ICI therapy (HR 2.0) [66]B2b, Down syndrome (IRR 3.67) [53]B2b. Vaccination (MMR, BCG) shows no association [57]B3a. Seasonal variation: peak in autumn/winter [76]D5. Pearl: The rapid global rise in T1DM incidence (3-4% per year) is too fast for genetic change and implicates environmental triggers, most consistently enteroviral infection in early childhood, while reassuringly, childhood vaccinations do not increase risk [2]A1a[57]B3a[76]D5.
| Factor | OR / RR | Evidence Level | Source |
|---|---|---|---|
| HLA-DR3/4-DQ2/8 heterozygosity | OR 20+ | 2b | [76]D5 |
| First-degree relative with T1DM | RR 15 | 2b | [76]D5 |
| Caesarean section delivery | OR 1.23 (95% CI 1.10-1.38) | 3a (meta-analysis, 20 studies) | [60]B3a |
| Early term birth (37-38 weeks) | RR 1.33 (95% CI 1.17-1.51) | 2a (meta-analysis) | [50]B2a |
| Enteroviral infection (in pregnancy or early childhood) | OR 2-3 | 2b | [76]D5 |
| Vitamin D insufficiency | OR 2-4 | 3b | [68]B3b |
| ICI therapy (PD-1/PD-L1) | HR 2.0 vs. no ICI | 2b | [66]B2b |
| Down syndrome | IRR 3.67 (95% CI 2.43-5.55) | 2b (registry, UK) | [53]B2b |
| Vaccination (routine childhood) | No increased risk (OR 1.0) | 3a (meta-analysis, 23 studies) | [57]B3a |
Clinical Presentation
- ▸T1DM may present with DKA, and DKA can occur despite continuous glucose monitoring, insulin pumps, or automated insulin delivery. [272]
- ▸Nausea, vomiting, abdominal pain, weakness, deep respirations, and altered consciousness are documented acute manifestations, but persistent abdominal findings require evaluation for an additional surgical or ischemic process. [93][274][275]
- ▸Overweight or obesity does not exclude pediatric T1DM and may worsen metabolic severity at presentation. [271]
- ▸Autoantibody-negative or atypical diabetes should prompt consideration of monogenic diabetes and other forms of diabetes. [270][94]
- ▸Rare presenting signs include bilateral cataracts, Mauriac syndrome, autoimmune neurologic disease, unusual glomerular disease, and advanced retinal detachment. [93][96][244][274][277]
Overview
Type 1 diabetes mellitus (T1DM) has a heterogeneous clinical presentation. The initial phenotype varies with age, residual β-cell function, body weight, autoantibody status, speed of β-cell loss, and associated autoimmune disease. In adults, distinguishing T1DM from insulin-treated type 2 diabetes can be particularly difficult because clinical features overlap, while disease progression and treatment requirements may differ substantially. [281]D Obesity and overweight do not exclude T1DM and may be associated with a more metabolically severe presentation in children. [271]
Initial presentation and diabetic ketoacidosis
New-onset T1DM may present with diabetic ketoacidosis (DKA), although the supplied studies do not establish a universal proportion for all populations. In a recent pediatric cohort, the severity of initial DKA was examined in relation to 25-hydroxyvitamin D concentrations and residual β-cell function, confirming DKA as a clinically important presentation of childhood-onset disease. [278]D Pediatric DKA may also be accompanied by transient thyroid-test abnormalities consistent with euthyroid sick syndrome; in a cohort of 182 children with T1DM admitted with DKA, thyroid function was assessed at presentation and again 2 weeks after DKA resolution to characterize recovery. [92]B2b
Among adults admitted with DKA in a German multicenter study, 64% of episodes occurred in people with pre-existing T1DM and 14% in people with newly diagnosed T1DM. DKA was observed despite continuous glucose monitoring in 51% of patients with established T1DM and despite insulin pumps or automated insulin-delivery systems in 24%, indicating that technology use does not eliminate risk. Seven episodes were associated with sodium–glucose cotransporter-2 inhibitors and were classified as euglycemic DKA. [272]C
Typical acute manifestations documented in the supplied cases include nausea, vomiting, abdominal pain, weakness, altered mental status or stupor, and deep or increased respirations. [93]C4[274]C[275]D Abdominal pain and gastrointestinal symptoms may improve with metabolic correction, but persistent or worsening abdominal findings should raise concern for another acute abdominal process. [275]D Severe insulin omission-associated DKA can be accompanied by extreme hyperglycemia, profound acidemia, hypobicarbonatemia, hypovolemia, and impaired tissue perfusion; one reported case had glucose 1,869 mg/dL, arterial pH 6.83, and bicarbonate 2.2 mmol/L, complicated by fulminant ischemic colitis. [275]D
Metabolic and anthropometric features
Excess body weight can worsen the metabolic presentation of pediatric T1DM, supporting the need to consider T1DM even in children who are overweight or obese. [271] Conversely, atypical presentations may suggest an alternative or additional diagnosis. A child with marked insulin resistance, overweight, a family history of type 2 diabetes, and transient glutamic acid decarboxylase antibody positivity was evaluated for glucokinase maturity-onset diabetes of the young, illustrating the diagnostic overlap between monogenic diabetes, T1DM, and type 2 diabetes. [94]C4
Autoantibody-negative and autoimmune presentations
Most children in the reported pediatric cohort were classified according to diabetes-associated autoantibodies, including GADA, IA-2A, ZnT8, IAA, and ICA; 1.4% were described as having monogenic diabetes despite a clinical diagnosis of T1DM, emphasizing that diabetes diagnosed in childhood is not invariably autoimmune. [270] Autoantibody-negative diabetes may therefore require reassessment of phenotype, endogenous insulin secretion, family history, and possible monogenic causes. [270]
T1DM may coexist with broader autoimmune syndromes. In autoimmune polyglandular syndrome type 1, stage 1 T1DM or islet autoimmunity may occur alongside hypoparathyroidism, candidiasis, vitiligo, anemia, and gastrointestinal disease; one patient initially presented with hypocalcemic convulsions and later developed chronic diarrhea and positive islet autoimmunity. [95]C4 GAD-antibody-associated neurological disease is another uncommon pattern: in a scoping review of 78 patients with T1DM and autoimmune encephalitis-associated epilepsy or seizures, T1DM preceded the neurological syndrome in 40%, followed it in 29%, and appeared concurrently in 9%. [277]D
Recognizable complications and unusual presenting signs
Poor insulin adherence and recurrent DKA can lead to severe chronic complications. Mauriac syndrome may present in an adolescent with longstanding poorly controlled T1DM, irregular meals, inconsistent glucose monitoring, recurrent DKA, abdominal pain, vomiting, weakness, deep respirations, cool extremities, hepatomegaly, and diminished distal pulses. [274]C
Bilateral cataracts can rarely precede the diagnosis of T1DM in children; idiopathic pediatric cataracts should therefore prompt consideration of diabetes screening even without systemic symptoms. [96]C4 Advanced diabetic retinal disease may present with tractional or combined tractional-rhegmatogenous retinal detachment requiring pars plana vitrectomy, including in young people with T1DM. [244] Renal presentations are not always attributable to diabetic nephropathy: a patient with a 19-year history of poorly controlled T1DM presented with nausea, vomiting, generalized edema, and proliferative glomerulonephritis with monoclonal IgG1-κ deposits. [93]C4
| Presentation pattern | Clinical features or context | Reference |
|---|---|---|
| DKA | Nausea, vomiting, abdominal pain, deep respirations, altered consciousness; may occur despite diabetes technology | [272]C[274]C[275]D |
| Severe DKA with abdominal emergency | Extreme hyperglycemia, profound acidemia, hypobicarbonatemia, diarrhea, vomiting, stupor, and ischemic colitis | [275]D |
| Chronic poor control/Mauriac syndrome | Recurrent DKA, irregular meals, poor insulin adherence, hepatomegaly, weakness, and peripheral hypoperfusion | [274]C |
| Atypical or associated disease | Cataracts, monoclonal glomerulonephritis, autoimmune encephalitis-associated seizures, or polyglandular autoimmunity | [93]C4[95]C4[96]C4[277]D |
Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
- ▸The supplied references do not establish a validated paired-hormone panel, dynamic test, or localization procedure for diagnosing type 1 diabetes mellitus. [135] [283] [284]
- ▸An exploratory study evaluated **40 serum microRNAs** in slowly progressive type 1 diabetes, type 2 diabetes, and healthy controls, but did not provide a clinical diagnostic threshold. [283]
- ▸A pediatric cohort of **639** patients assessed autoimmune disease frequency and reviewed autoantibody data, supporting attention to autoimmune comorbidity rather than a specific dynamic endocrine test. [284]
- ▸The supplied imaging and biomarker studies concern diabetes complications or associated disease, not anatomical localization of the primary diabetes process. [263] [286] [287] [288]
Scope of the available evidence
The supplied literature does not provide a validated diagnostic algorithm for type 1 diabetes mellitus (T1DM) based on paired hormone measurements, dynamic endocrine testing, or anatomical localization. The available studies are predominantly observational and address autoimmune comorbidity, emerging biomarkers, obesity, or diabetes complications rather than the initial biochemical confirmation of T1DM. [135]B2a [283] [284] Consequently, no hormone-pair threshold, stimulation or suppression-test protocol, imaging pathway, or localization procedure can be recommended from these references alone. [135]B2a [283] [284]
Biochemical confirmation and classification
The supplied references do not report diagnostic glucose or HbA1c thresholds for diabetes, nor do they define a paired-hormone strategy for distinguishing T1DM from other diabetes phenotypes. [135]B2a [283] [284] They also do not establish dynamic testing of endogenous insulin secretion as a required diagnostic step. [283] In the available evidence, classification is instead represented clinically through pre-existing diagnostic categories: one biomarker study compared patients with slowly progressive T1DM, type 2 diabetes mellitus, and healthy controls, while examining serum microRNA expression at diagnosis. [283]
Okuma and colleagues studied 40 serum microRNAs in adults with definite slowly progressive T1DM, T2DM, and healthy controls; quantitative real-time polymerase chain reaction was used, and miRNAs showing significant between-group differences were subsequently evaluated with logistic regression. [283] This is exploratory biomarker evidence, not a validated replacement for routine diabetes classification, and the reference does not establish a threshold suitable for clinical diagnosis or localization. [283]
Autoimmune assessment and associated disease
Autoimmune evaluation is clinically relevant because children and adolescents with T1DM have an increased risk of additional autoimmune diseases. [284] In a retrospective cohort of 639 children and adolescents followed at a tertiary pediatric endocrinology center, investigators reviewed demographic, clinical, laboratory, and autoantibody data to assess the frequency, spectrum, and timing of autoimmune disease. [284] The study supports systematic attention to autoimmune comorbidity but does not establish a paired-hormone test or a dynamic test for diagnosing pancreatic autoimmune destruction. [284]
The supplied literature also includes a nationwide cohort study examining autoimmune diseases during the 10 years preceding myasthenia gravis diagnosis in adults aged ≥20 years. [282] This study concerns temporal autoimmune associations in myasthenia gravis rather than T1DM diagnosis and therefore cannot be used to define a T1DM localization or endocrine-testing protocol. [282]
Pediatric celiac disease is another relevant immune-mediated condition in the supplied evidence. A single-center study of 58 children with confirmed celiac disease applied the 2020 ESPGHAN diagnostic criteria, including non-biopsy confirmation in selected cases. [292]C This supports awareness of coexisting immune-mediated disease in pediatric practice, but it does not provide a T1DM diagnostic threshold, paired-hormone approach, or pancreatic imaging indication. [292]C
Imaging, localization, and complication-directed testing
None of the supplied studies demonstrates a role for pancreatic imaging or other anatomical localization in routine T1DM diagnosis. [135]B2a [283] [284] Brain MRI studies reported thalamic or functional brain alterations in patients with established T1DM, but these findings concern disease-associated neuroimaging rather than localization of diabetes etiology. [263] [287]C
Renal testing in established T1DM should be interpreted as complication assessment rather than diagnostic localization. A pediatric case-control study described microalbuminuria as the current standard for diagnosis and staging of diabetic kidney disease, while evaluating urinary fatty acid-binding protein 1 as a possible marker of proximal tubular injury. [288] The study does not validate FABP1 for diagnosing T1DM itself or for identifying pancreatic disease. [288] Similarly, liver ultrasonography and noninvasive fibrosis indices have been investigated in adults with T1DM, but this work addresses metabolic dysfunction-associated steatotic liver disease and fibrosis rather than diabetes classification. [286]
Practical evidence boundary
Based strictly on the supplied references, the workup should distinguish established diagnostic testing from research applications: serum microRNA panels remain investigational; autoimmune comorbidity assessment may be clinically relevant; and renal, hepatic, retinal, neurological, or other imaging tests evaluate complications or associated disease rather than localize the cause of T1DM. [283] [284] [286] [287]C [288] No supplied reference supports routine paired hormones, dynamic endocrine testing, or anatomical localization as requirements for diagnosing T1DM. [135]B2a [282] [283] [284]
| Domain | Evidence from supplied references | Interpretation |
|---|---|---|
| Paired hormones | No validated hormone pair or threshold is reported. [135]B2a [283] [284] | Cannot recommend a paired-hormone diagnostic protocol. |
| Dynamic testing | No stimulation or suppression test is established for T1DM diagnosis. [283] | Not supported as routine testing by these references. |
| Autoimmunity | Pediatric T1DM cohorts include laboratory and autoantibody assessment; additional autoimmune disease is clinically relevant. [284] | Supports comorbidity assessment, not a specific localization test. |
| Emerging biomarkers | 40 serum microRNAs were studied in slowly progressive T1DM, T2DM, and healthy controls. [283] | Research-stage evidence; no validated clinical cutoff is provided. |
| Imaging/localization | MRI, liver ultrasonography, and renal biomarkers were studied in established T1DM or its complications. [263] [286] [287]C [288] | These tests do not localize the cause of T1DM. |
Severity, Staging and Risk Stratification
- ▸No universally accepted global severity or staging system for T1DM is established by the supplied evidence; risk assessment should remain domain-specific [245][149][82].
- ▸Advanced retinal disease should be characterized by the presence and anatomical complexity of proliferative retinopathy, TRD, or combined tractional rhegmatogenous detachment; a proposed TRD staging system exists, but its definitions are not provided in the available abstract [244].
- ▸Albuminuria, kidney function, vascular ultrasound findings, neuropathy assessment, and retinal examination represent complementary microvascular and macrovascular risk domains [294][296][288][256][82].
- ▸Low-grade UACR, FABP1, triglyceride-glucose index, plantar fascia thickness, outer-retinal biomarkers, and inflammatory markers are investigational or adjunctive markers and lack universally transferable clinical thresholds in the supplied evidence [294][296][288][256][244][298].
- ▸Inpatient hypoglycaemia prediction and residual C-peptide assessment may refine individualized risk, but neither replaces longitudinal clinical assessment [149][245].
Scope and principles
Severity in type 1 diabetes mellitus (T1DM) is multidimensional rather than defined by a single laboratory value. Clinically relevant domains include glycaemic instability, residual β-cell function, acute metabolic risk, microvascular disease, macrovascular remodeling, neuropathy, bone and periodontal complications, and comorbidity or phenotype-specific risk. The evidence supplied here is predominantly observational, retrospective, cross-sectional, or biomarker-based; therefore, it supports risk characterization more strongly than a universally validated global T1DM severity score [245][82]B3b[296][288].
Glycaemic and metabolic severity
Risk stratification should begin with the frequency and consequences of dysglycaemia, including hypoglycaemia, hyperglycaemia, and hospitalization. A multicentre Chinese study developed and externally validated an interpretable machine-learning model for in-hospital hypoglycaemia in adults with T1DM using data from five tertiary hospitals; the study population comprised adults hospitalized between 2019 and 2025, with a 7:3 development-to-validation split, but the supplied evidence does not provide the final predictor list or clinical cut-offs [149]B2b. This model may assist inpatient risk prediction, but it should not be treated as a validated measure of overall diabetes severity [149]B2b.
Residual endogenous insulin secretion is another potential stratifier. In a prospective observational study of 393 adults with newly diagnosed diabetes, fasting and glucagon-stimulated C-peptide were assessed at diagnosis across diabetes phenotypes, including classical adult-onset autoimmune T1DM and latent autoimmune diabetes in adults; 89 participants were reassessed after a mean of 7 years [245]. The available abstract does not provide T1DM-specific C-peptide thresholds, but it supports baseline β-cell secretory reserve as a clinically relevant phenotype variable rather than a standalone staging system [245]. Autoimmune classification may also refine risk assessment: in a Dutch pediatric cohort diagnosed before 18 years, diabetes-associated autoantibodies included GADA, IA-2A, ZnT8, IAA, and ICA; the supplied abstract reports a cohort of 562 patients but does not provide complete comparative severity results [270]. Screening of 2–18-year-old first-degree relatives in a Turkish multicentre cohort measured ZnT8A, GADA, IAA, and IA-2A and provides information on autoimmune risk detection, not established disease severity [145]C4.
Microvascular staging
Retinopathy
Diabetic retinopathy (DR) should be staged by ophthalmic findings, with proliferative disease and retinal detachment representing advanced ocular complications. A retrospective Riyadh cohort followed 449 individuals with T1DM aged ≥9 years from 2015 to 2025 to estimate DR incidence and identify demographic and systemic predictors; the supplied abstract does not report incidence estimates, stage-specific thresholds, or the final predictor effect sizes [82]B3b. In a T1DM cohort undergoing pars plana vitrectomy, tractional retinal detachment (TRD) and combined tractional rhegmatogenous retinal detachment were evaluated, and the investigators proposed a TRD staging system [244]. However, the available evidence does not describe the proposed stage definitions, so these should not be reproduced as established criteria. The study also examined tamponade selection and outer-retinal structural biomarkers as prognostic factors for visual outcomes, indicating that anatomic complexity and retinal structural integrity may refine risk among patients with advanced retinopathy [244].
Kidney disease
Kidney risk should be stratified using albuminuria and estimated glomerular filtration rate, while recognizing that albuminuria may not capture early tubular injury. In adolescents with T1DM, low-grade urinary albumin-to-creatinine ratio (UACR) was investigated alongside a carotid or femoral arterial “triple-line pattern” as a marker of early peripheral vascular remodeling; the cohort included 283 adolescents with T1DM and 106 matched controls [294]. The abstract does not specify the UACR thresholds, so no numerical albuminuria cut-off can be assigned from this evidence. In adults, a retrospective study of 210 T1DM patients examined the triglyceride-glucose index in relation to diabetic kidney disease (DKD), comparing 150 participants without DKD with 60 participants with DKD and analyzing index tertiles [296]. In children, urinary FABP1 was studied as a possible marker of proximal tubular damage in 30 T1DM patients with DKD, 30 without DKD, and 30 controls; the study explicitly contrasts FABP1 with microalbuminuria, which may reflect more established renal injury [288]. These biomarkers remain investigational in the supplied evidence and should complement, not replace, conventional kidney assessment [288][296].
Vascular, neurological, skeletal and infectious risk
Early vascular risk may be present before conventional carotid intima-media thickness becomes abnormal. The adolescent SCVD-T1DM cohort evaluated common carotid and common femoral artery ultrasound and found the combination of low-grade albuminuria and the triple-line pattern relevant to peripheral remodeling [294]. Peripheral neuropathy risk was explored in 290 adults with T1DM using plantar fascia thickness measured by ultrasound; measurements were associated with clinical neuropathy evaluation, advanced glycation end products, and diabetes-related clinical variables, but the evidence does not establish diagnostic thresholds [256]. Bone risk was assessed in a cross-sectional comparison of 76 people with T1DM, 91 with T2DM, 40 with LADA, and 85 controls using advanced glycation end products, sclerostin, bone mineral density, and vertebral-fracture assessment; the supplied abstract does not provide T1DM-specific fracture thresholds [299].
Periodontal disease and altered oral microbiome profiles were examined in adolescents with T1DM, comparing 20 participants with periodontal disease, 20 without periodontal disease, and 20 siblings with periodontal disease; differences included several bacterial taxa, but microbiome findings are not yet a validated severity scale [300]. Poor metabolic control, higher HbA1c, and more frequent hyperglycaemia were associated with impaired epidermal barrier measurements in 125 children and adolescents with T1DM aged 6–18 years, although these dermatological measures are adjunctive rather than standard diabetes-staging tools [297].
Comorbidity and contextual risk
T1DM-associated risk is modified by autoimmune and infectious comorbidity. A pediatric celiac-disease cohort examined anti-TPO, anti-GAD, and anti-insulin antibodies in relation to histopathological severity, but it does not establish a T1DM staging threshold [12]B3b. Thyroid eye disease severity was studied in patients with Graves disease and autoimmune polyglandular syndromes, including individuals with moderate-to-severe active disease requiring high-dose intravenous steroids; this evidence concerns associated autoimmune disease rather than T1DM severity [295]C. A nationwide study of autoimmune diseases preceding myasthenia gravis similarly provides contextual autoimmune epidemiology, not a T1DM risk score [282]. Pediatric emphysematous pyelonephritis was identified as a rare life-threatening infection in a systematic review of 20 studies involving 21 patients; diabetes was not presented in the supplied abstract as a T1DM-specific staging marker [91]C4. Finally, studies of COVID-19 in T1DM examined cytokines, inflammatory markers, genetic polymorphisms, and IL-18 as a predictor of disease severity, while a murine spinal implant-infection model compared T1DM, T2DM, and nondiabetic animals; these findings may inform acute illness risk but cannot define routine T1DM staging [298][261].
| Domain | Evidence-supported indicators | Interpretation and limitations |
|---|---|---|
| Glycaemic instability | Inpatient hypoglycaemia prediction; hyperglycaemia and HbA1c-related measures | Useful for acute-risk assessment; no universal overall severity threshold is supplied [149]B2b[297] |
| β-cell reserve and phenotype | Fasting or glucagon-stimulated C-peptide; diabetes-associated autoantibodies | Helps characterize phenotype and residual secretion; T1DM-specific staging cut-offs are not supplied [245][270] |
| Retinopathy | DR incidence surveillance; TRD or combined TRRD anatomy; outer-retinal biomarkers | Advanced retinal anatomy carries high visual risk; proposed TRD stages require validation and the definitions are unavailable here [82]B3b[244] |
| Kidney and vascular disease | UACR, DKD status, TyG index, FABP1, carotid/femoral ultrasound | Early remodeling and tubular injury may precede conventional findings; biomarkers remain adjunctive [294][296][288] |
| Neuropathy, skeletal and periodontal complications | Clinical neuropathy assessment, plantar fascia thickness, AGEs, sclerostin, BMD, vertebral fractures, periodontal examination | Associated with complication burden in observational studies but not validated as formal stages [256][299][300] |
| Acute comorbidity | Severe infection, COVID-19 inflammatory markers, autoimmune disease | Contextual modifiers of short-term risk rather than routine T1DM stages [91]C4[298][295]C[282][261] |
Acute Management and Endocrine Emergencies
- ▸DKA should be treated as a medical emergency; the supplied references do not provide complete biochemical diagnostic thresholds or a full treatment protocol. [74][274][293]
- ▸Recurrent or unexplained DKA should prompt nonjudgmental assessment for intentional insulin omission, eating-disorder pathology, infection, and access or adherence barriers. [74][293]
- ▸AID evidence in children younger than 7 years comes from four randomized trials involving 292 participants, but pooled acute-event estimates are not available in the supplied abstract. [131]
- ▸GLP-1 receptor agonists are adjunctive investigational therapies in T1D, not emergency treatments; the meta-analysis found neutral overall hypoglycaemia risk but incomplete DKA reporting in the supplied abstract. [39]
- ▸Perioperative AID evidence cited here is not directly applicable to T1D because the randomized pilot excluded T1D. [301]
Scope and priorities
Acute management in type 1 diabetes mellitus (T1D) must prioritize recognition and treatment of diabetic ketoacidosis (DKA), severe hypoglycaemia, insulin interruption, and acute illness, while maintaining sufficient insulin to prevent ketosis. The references supplied do not provide a complete, validated DKA treatment protocol; therefore, fluid resuscitation, insulin infusion, electrolyte replacement, cerebral-injury monitoring, and transition back to subcutaneous insulin should follow local pediatric or adult emergency protocols rather than being inferred from the studies cited here. DKA is a potentially life-threatening complication of T1D and is specifically reported in association with intentional insulin omission, immune checkpoint inhibitor-induced diabetes, and several case reports. [74]D5[303][274]C[293]C
Suspected diabetic ketoacidosis
Suspect DKA when a person with T1D develops vomiting, abdominal pain, weakness, dehydration, tachypnoea or deep breathing, altered mental status, or unexplained hyperglycaemia; however, the supplied evidence does not define diagnostic glucose, ketone, or pH thresholds. A 14-year-old with recurrent DKA had poor insulin adherence, irregular meals, and inconsistent glucose monitoring, presenting with abdominal pain, vomiting, weakness, mildly increased deep regular breathing, cool extremities, and abdominal tenderness. [274]C Another adolescent developed rhino-orbital-cerebral mucormycosis after DKA, emphasizing the need to investigate severe infection when fever, facial pain, orbital symptoms, neurological findings, or clinical deterioration accompany or follow DKA. [293]C
Intentional insulin omission (“diabulimia”) is a high-risk behavior predominantly described in adolescents and young adults; the reviewed evidence links it with DKA, microvascular complications, and increased mortality. [74]D5 Assessment during recurrent or unexplained DKA should therefore include nonjudgmental screening for insulin omission, eating-disorder symptoms, weight-control behaviors, psychosocial distress, and access to insulin, with urgent multidisciplinary intervention when indicated. [74]D5
Hypoglycaemia and glucose monitoring
Severe hypoglycaemia is a principal acute safety outcome in T1D research. A nationwide pediatric cohort study evaluated the association between continuous glucose monitoring (CGM) and DKA or severe hypoglycaemia in children and adolescents younger than 19 years, but the supplied abstract does not report the adjusted hazard-ratio results; it therefore cannot establish the magnitude of protection in this section. [166]B2b A 2026 Cochrane review found that evidence remains limited and inconsistent regarding the optimal timing, frequency, and glycaemic targets for self-monitoring of blood glucose in adults with T1D, particularly in relation to clinically meaningful outcomes and low-resource settings. [273]
For very young children, automated insulin delivery (AID) is supported by a systematic review and meta-analysis of four randomized controlled trials involving 292 participants younger than 7 years. The prespecified primary endpoint was CGM time in range (70–180 mg/dL), with secondary outcomes including glycated haemoglobin, other CGM metrics, insulin dose, severe hypoglycaemia, and DKA; the supplied abstract does not provide the pooled effect estimates, so numerical claims about acute-event reduction should not be made from this citation alone. [131]A1a CGM and AID should be regarded as tools that may support detection and prevention of dysglycaemia, not substitutes for confirmatory assessment and emergency treatment when symptoms, ketones, or device failure suggest DKA or severe hypoglycaemia. [131]A1a[166]B2b[306]
Adjunctive drugs and ketoacidosis risk
GLP-1 receptor agonists remain investigational adjuncts to insulin in T1D and are not established emergency treatments. A systematic review and meta-analysis of 25 studies reported neutral pooled risks for overall hypoglycaemia (RR 1.01; moderate certainty) and serious adverse events (RR 0.89; moderate certainty), with no significant increase in severe hypoglycaemia (RR 0.74; low certainty); gastrointestinal adverse effects, withdrawals, and DKA were also evaluated, although the supplied abstract does not provide the complete DKA estimate. [39]A1a
Sodium-glucose cotransporter-2 inhibitors have also been studied as adjuncts to insulin in T1D, but the supplied meta-analysis addresses fracture risk and does not provide sufficient results to define acute DKA safety or recommend their use during illness. [302] In practice, any adjunctive glucose-lowering therapy should be reviewed during vomiting, dehydration, fasting, infection, or suspected ketosis, with urgent ketone testing and specialist advice rather than medication escalation. [302][39]A1a
Perioperative and treatment-related emergencies
Perioperative insulin management requires a documented institutional protocol, frequent glucose assessment, and coordination among anesthesia, surgery, and diabetes teams. The cited randomized pilot of open-source hybrid closed-loop AID studied patients with diabetes excluding T1D and therefore cannot establish safety or efficacy for people with T1D undergoing surgery. [301] A single-center case series of simultaneous pancreas-kidney transplantation included patients with T1D or T2D and explored a six-phase intraoperative glycaemic algorithm, but its retrospective design and sample of 11 patients limit generalization. [305]C
Immune checkpoint inhibitor-induced T1D is a rare but potentially life-threatening endocrine immune-related adverse event; a systematic review and meta-analysis evaluated incidence, DKA occurrence, treatment exposure, and prognostic associations, but the supplied abstract does not report the pooled numerical estimates. [303] New hyperglycaemia, ketosis, or DKA during immune checkpoint inhibitor therapy warrants urgent endocrine assessment and consideration of insulin-dependent diabetes. [303]
Special acute considerations
Exercise can produce acute cardiovascular and glycaemic changes in adults with T1D. In a small randomized crossover study of 12 adults, perceived exertion was associated with cardiovascular strain but not glycaemic response during approximately 30-minute aerobic and resistance sessions; the findings do not replace glucose and ketone precautions around exercise. [162]A1b Continuous glucose monitoring has been reviewed as a technology with potential effects on diabetes outcomes, costs, and limitations across major commercial platforms, but the supplied review does not provide a treatment algorithm for emergencies. [306]
A patient with T1D and recurrent DKA, poor glycaemic control, hepatomegaly, growth abnormalities, or musculoskeletal features may require assessment for rare complications such as Mauriac syndrome; the cited case involved a 14-year-old with longstanding T1D, recurrent DKA, irregular meals, poor monitoring, and inconsistent insulin adherence. [274]C These presentations reinforce that emergency stabilization must be accompanied by investigation of adherence barriers, infection, eating disorders, device problems, and endocrine or systemic comorbidity. [74]D5[274]C[293]C
| Presentation or context | Immediate priority | Evidence limitation |
|---|---|---|
| Vomiting, abdominal pain, dehydration, deep breathing, or suspected ketosis | Urgent DKA evaluation and protocolized emergency treatment | Diagnostic and treatment thresholds are not supplied in the cited abstracts. [274]C[293]C |
| Recurrent or unexplained DKA | Assess insulin omission, eating-disorder symptoms, infection, device problems, and psychosocial barriers | Intentional insulin omission is associated with DKA and serious long-term consequences. [74]D5 |
| Severe hypoglycaemia risk | Immediate rescue treatment and review of insulin, monitoring, and technology use | Pediatric CGM hazard-ratio results are not reported in the supplied abstract. [166]B2b |
| Surgery or prolonged fasting | Use a documented perioperative insulin and glucose-monitoring protocol | Direct T1D randomized evidence for open-source AID is unavailable in the cited pilot. [301] |
| Immune checkpoint inhibitor exposure with new hyperglycaemia or ketosis | Urgent endocrine evaluation for ICI-induced T1D and DKA | Pooled incidence and DKA estimates are not reported in the supplied abstract. [303] |
Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
- ▸Use individualized insulin replacement with CGM-informed targets; one study-defined profile was TIR 70–180 mg/dL **>70%**, CV **<36%**, and TBR <70 mg/dL **<5%**. [311]
- ▸Evidence for optimal SMBG timing, frequency and target values remains limited and inconsistent. [273]
- ▸Pump, hybrid closed-loop and alternative insulin-delivery strategies are active areas of evidence, but several supplied studies do not report comparative outcome estimates. [192][309][313][314][164]
- ▸Address exercise, sleep, obesity and psychological burden as components of long-term management rather than treating HbA1c in isolation. [135][162][307][310]
- ▸Stem-cell therapy and BCG vaccination remain investigational or uncertain; neither is established as routine definitive therapy on the supplied evidence. [308][312]
- ▸Irregular insulin use and monitoring can result in recurrent DKA and severe complications, particularly in adolescents. [274]
Treatment framework
Long-term management of type 1 diabetes (T1D) should be organized around individualized glycaemic targets, prevention of hypoglycaemia and diabetic ketoacidosis (DKA), preservation of quality of life, and reduction of cardiovascular, renal, neurologic and other diabetes-related risk. The supplied 2026 evidence base chiefly evaluates insulin delivery, glucose monitoring, exercise, sleep, psychological burden, obesity, adjunctive pharmacotherapy and emerging disease-modifying treatment rather than replacing insulin as established therapy. [192]A1a
Replacement: insulin and glucose-directed therapy
Insulin replacement remains the therapeutic foundation; once-weekly insulin efsitora is being evaluated as an alternative to once-daily basal insulin in people with type 1 or type 2 diabetes, with HbA1c and level 1, 2 and 3 hypoglycaemia as principal outcomes, but the supplied abstract does not provide comparative results sufficient to establish routine T1D use. [192]A1a A Cochrane network meta-analysis is assessing ultra-short-acting insulin analogues versus regular human insulin and other ultra-short-acting analogues in adults with T1D using multiple daily injections; the available abstract identifies the comparative question but does not report the treatment ranking or effect estimates. [164]A1a
Pump-based delivery and automated insulin systems are supported by contemporary implementation and observational evidence. A real-world Chinese survey of 47 adults using a switchable tubeless/tubed two-in-one pump for at least 3 months reported a mean HbA1c of 7.2% ± 1.4% before the survey and collected sensor-derived time-in-range and patient-experience outcomes, although its descriptive, self-reported design limits causal inference. [313]C In adults initiating the MiniMed 780G advanced hybrid closed-loop system, virtual and in-person training were compared for 12-week metabolic and safety outcomes; the supplied abstract describes the comparison but does not provide the final between-group results. [314] A U.S. nationwide readmissions analysis examined whether pump use was associated with 30-day readmission and in-hospital mortality among adults hospitalized with T1D, but the supplied abstract does not state the estimates. [309]
Continuous glucose monitoring (CGM) permits target-based assessment beyond HbA1c. One adult study defined an on-target profile as time in range (TIR; 70–180 mg/dL [3.9–10.0 mmol/L]) >70%, coefficient of variation <36%, and time below range (TBR; <70 mg/dL [<3.9 mmol/L]) <5%. [311] These thresholds were used to stratify 325 adults for metabolomic analysis and should be interpreted as study-defined clinical targets rather than evidence that metabolomic testing should guide routine treatment. [311] A Cochrane review found that evidence remains limited and inconsistent regarding the optimal timing, frequency and target values for self-monitoring of blood glucose in adults with T1D, particularly in low-resource settings. [273]
Suppression and adjunctive strategies
Adjunctive therapies require careful selection because evidence is heterogeneous and safety may limit their role. A systematic review and meta-analysis of GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors included five T1D studies within 36 randomized trials and focused on lean body mass; the supplied abstract does not report T1D-specific efficacy or safety estimates. [31]A1a Pediatric obesity and T1D have a bidirectional relationship, with the review examining obesity-associated T1D risk, post-diagnostic weight trajectories and metabolic outcomes; weight management should therefore avoid compromising insulin delivery or nutritional adequacy. [135]B2a
Lifestyle treatment remains part of target attainment. In an exploratory randomized crossover study of 12 adults with T1D, perceived exertion was associated with cardiovascular strain but not with the acute glycaemic response to approximately 30-minute aerobic or resistance sessions; this supports monitoring cardiovascular and glucose responses rather than assuming that exertion ratings predict glucose change. [162]A1b Objective sleep and circadian measures in adolescents with T1D were systematically reviewed for associations with glycaemic outcomes, highlighting sleep and circadian health as relevant domains for individualized management, although the supplied abstract does not report pooled effects. [307] Psychological support is also clinically relevant: in an app-derived sample of 101 adults, concerns about future complications were reported by 85.1%, while guilt or worry when diabetes was “out of control,” diabetes burnout and the feeling that diabetes controls life were each reported by 72.3%; network modeling identified a densely connected psychological-burden domain. [310]
Definitive or disease-modifying treatment
Stem-cell therapy remains investigational. A 2026 systematic review and meta-analysis included eight reports from seven randomized trials involving 169 participants and evaluated HbA1c, fasting C-peptide, insulin-dose reduction, insulin independence and adverse events; the supplied abstract does not provide pooled effect sizes, so it cannot establish stem-cell therapy as routine care. [308] BCG vaccination is likewise adjunctive and unsettled: a systematic review reported supportive studies describing C-peptide improvement, HbA1c reduction, partial beta-cell recovery and tumor-necrosis-factor-related immunomodulation, but also identified opposing evidence. [312]
Immune checkpoint inhibitor-induced T1D is a distinct secondary form of insulin-deficient diabetes. A systematic review and meta-analysis evaluated its incidence, DKA occurrence, risk factors including dual versus monotherapy exposure, and prognostic implications in adults receiving cancer immunotherapy; these findings inform surveillance and acute management of ICI-associated diabetes rather than routine treatment of autoimmune T1D. [303]
Evidence boundaries and safety
Several supplied studies do not directly inform chronic T1D treat-to-target therapy: pediatric emphysematous pyelonephritis concerns a rare renal infection, thyroid eye disease research concerns Graves-associated ophthalmopathy, and glargine research concerns dexamethasone-induced hyperglycaemia in patients explicitly excluding T1D. [91]C4[295]C[315]C A Mauriac syndrome case illustrates the consequences of irregular meals, inconsistent monitoring and poor insulin adherence, with recurrent DKA in an adolescent, reinforcing the need for reliable insulin administration and follow-up. [274]C Long-term targets should therefore be negotiated with the person with T1D, prioritizing safety, feasibility, psychosocial wellbeing and avoidance of severe hypoglycaemia or DKA while using CGM, injection or pump therapy, and adjunctive interventions according to the strength and applicability of evidence. [273][307][310][313]C[314][274]C
| Domain | Evidence or threshold | Management implication |
|---|---|---|
| CGM | TIR 70–180 mg/dL >70%; CV <36%; TBR <70 mg/dL <5% [311] | Review time in range, variability and hypoglycaemia together |
| Insulin replacement | Efsitora, ultra-short-acting analogues, pumps and hybrid closed-loop systems are being evaluated [192]A1a[164]A1a[313]C[314] | Select delivery method according to safety, access, training and patient preference |
| Self-monitoring | Optimal timing, frequency and targets remain uncertain [273] | Individualize monitoring, especially where CGM is unavailable |
| Adjunctive or definitive therapy | GLP-1RA/SGLT2i, stem cells and BCG have incomplete or mixed T1D evidence [31]A1a[308][312] | Use only with specialist assessment and explicit discussion of uncertainty |
History and Evolution of Treatment
- ▸Lifelong insulin replacement remains the foundation of T1DM treatment because autoimmune β-cell destruction causes absolute insulin deficiency.[220]
- ▸MDI continues to be used in adults, but severe hypoglycemia risk requires structured prediction and prevention.[320]
- ▸CSII and CGM enable technology-supported individualized care; faster insulin aspart is being evaluated as a refinement of pump-based prandial treatment in children with HbA1c <8%.[316]
- ▸Education, tele-nursing, exercise planning, and family support are increasingly integrated into treatment.[162][323]
- ▸Prebiotics, microbiome-directed strategies, and immune biomarkers remain investigational rather than established disease-modifying therapies.[186][259][318][325]
- ▸Contemporary management includes DKA prevention, screening for thyroid and islet autoimmunity, assessment of atypical diabetes, vaccination review, and surveillance for neurologic, cognitive, renal, and oral complications.[84][93][94][145][220][270][319][321][322][324]
From insulin replacement to individualized intensive therapy
Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of pancreatic β-cells and consequent absolute insulin deficiency; therefore, treatment remains based on lifelong insulin replacement, with dosing adjusted to prevent both hyperglycemia and hypoglycemia.[220]A1a The supplied evidence does not directly document the earliest historical milestones of insulin discovery or the transition from animal-derived to recombinant insulin. It does, however, show the continuing evolution from conventional insulin replacement toward technology-supported, individualized care.
Multiple daily injections and prevention of acute complications
Multiple daily injections (MDI) remain an established treatment strategy, particularly in adults. The SEHYPAN multicenter case-control study evaluated adults with T1DM treated with MDI and focused on severe hypoglycemia requiring prehospital emergency care, underscoring that insulin treatment must be accompanied by structured risk assessment and preventive planning.[320] A predictive model for severe hypoglycemia is clinically relevant because severe events are associated with morbidity, mortality, and impaired quality of life.[320] In children, severe hypoglycemia is also a major concern because younger patients may have limited symptom recognition and changing insulin sensitivity during growth and hormonal development.[220]A1a
Poor adherence, irregular meals, and inadequate glucose monitoring can undermine injection-based treatment. A case of recurrent diabetic ketoacidosis (DKA), hepatomegaly, and Mauriac syndrome in an adolescent receiving mealtime insulin aspart and bedtime insulin glargine illustrates the consequences of inconsistent insulin use and monitoring.[274]C DKA remains potentially fatal; a retrospective Ethiopian cohort specifically evaluated its incidence and predictors among adults with T1DM, emphasizing the importance of uninterrupted insulin access, education, sick-day management, and timely treatment of precipitating factors.[84]B2b
Insulin pumps, continuous glucose monitoring, and faster analogues
Treatment has progressively incorporated continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM). In a prospective randomized crossover trial of children and adolescents aged 6–17 years with at least 1 year of T1DM, at least 3 months of pump use, CGM use, and HbA1c <8%, faster insulin aspart (FIA) was compared with standard insulin aspart (SIA) during two four-week treatment phases.[316] This study specifically addressed whether changing the prandial insulin analogue improves time in range (TIR) in pump-treated youth whose glycemia was already close to target; it therefore represents refinement of established CSII-and-CGM therapy rather than a replacement for insulin delivery technology.[316]
Education, remote support, and behavioral care
Modern treatment increasingly extends beyond the prescription itself. In a randomized controlled study of 67 adolescents aged 12–18 years, six months of telephone-based tele-nursing follow-up for adolescents and parents was evaluated after face-to-face education, with outcomes including metabolic control, self-efficacy, quality of life, and anxiety.[323] This approach reflects a shift toward ongoing education, remote monitoring, and family-centered support rather than episodic clinic-based instruction alone.[323]
Exercise is another component of comprehensive treatment. An exploratory randomized crossover trial in 12 adults with T1DM compared approximately 30-minute aerobic interval and resistance-training sessions and examined perceived exertion, enjoyment, heart rate, and capillary glucose responses.[162]A1b The study addressed whether low-cost psychophysiological measures could help characterize cardiovascular strain and acute glycemic responses when continuous clinical monitoring is impractical, although its exploratory design and small sample limit generalization.[162]A1b
Emerging adjunctive and disease-modifying approaches
Adjunctive therapies remain investigational. A double-blind randomized pilot trial assigned 68 children aged 8–18 years with established T1DM to 8 g/day oligofructose-enriched inulin or isocaloric maltodextrin for 12 weeks, assessing HbA1c and stool microbiome composition.[186]A1b Related work on the gut–brain axis emphasizes that microbiome associations with obesity and T1DM remain mechanistic and prospective research questions, requiring studies capable of distinguishing correlation from causation before therapeutic application.[259]
Immunologic and biomarker research may eventually support disease-modifying treatment, but it is not yet established therapy. Increased ADAM19 expression in dendritic cells was investigated in relation to immune features and lower C-peptide levels, while IL-6 and oncostatin M were measured in children with T1DM in relation to glycemic indices.[318][325] These observational findings describe potential biological targets, not proven interventions.[318][325]
Prevention, screening, and complication-informed care
The treatment paradigm has expanded toward earlier identification of risk. Screening first-degree relatives aged 2–18 years for ZnT8A, GADA, IAA, and IA-2A was used to assess autoantibody prevalence, determinants, and the psychological effects of result disclosure.[145]C4 Familial T1DM was uncommon in a Korean multicenter pediatric cohort, occurring in 3.4% of index children, but family history remains clinically relevant for case finding and counseling.[317] Autoantibody-negative diabetes and the distinction from monogenic diabetes also require diagnostic reassessment: a Dutch pediatric cohort characterized autoantibody-positive and autoantibody-negative cases, while a reported GCK variant with transient GADA positivity illustrates the risk of misclassification and inappropriate treatment.[270][94]C4
Care now also includes screening for associated autoimmune disease and long-term complications. Thyroid autoantibodies were evaluated at diagnosis in children and adolescents with T1DM alongside islet autoantibodies.[321] Severe hypoglycemia prevention is important not only acutely but also because childhood severe hypoglycemia has been reviewed for possible neurodevelopmental effects.[220]A1a Brain volumetric and cognitive consequences have been examined in young adults with long-standing T1DM, and oral sensory neuropathy has been reported in both early hyperaesthetic and later hypoesthetic forms.[319][322]C Renal presentations may not always be attributable to diabetic nephropathy, as illustrated by a case of proliferative glomerulonephritis with monoclonal IgG1-κ deposition in a patient with 19 years of T1DM.[93]C4
Finally, comprehensive care includes general preventive medicine. A case-control study found diminished hepatitis B antibody responses in pediatric patients with T1DM and raised the possibility of revaccination protocols for those without protective serologic responses.[324] Thus, contemporary T1DM treatment has evolved from insulin replacement alone into an integrated model combining MDI or CSII, CGM, safer glycemic targets, education, remote support, exercise planning, complication surveillance, family-risk assessment, and carefully evaluated experimental adjuncts.[162]A1b[186]A1b[220]A1a[316][320][323]
| Treatment phase | Main approach | Evidence represented in the supplied references |
|---|---|---|
| Insulin replacement | Lifelong insulin with adjustment to avoid hyperglycemia and hypoglycemia | Absolute insulin deficiency and severe hypoglycemia concerns are described in children and adults.[220]A1a[320] |
| Intensive injection therapy | MDI using basal and mealtime insulin, with adherence and sick-day education | MDI-associated severe hypoglycemia and recurrent DKA are documented.[274]C[320] |
| Technology-supported therapy | CSII plus CGM, with evaluation of faster prandial insulin analogues | FIA versus SIA was studied in pump-treated youth with HbA1c <8%.[316] |
| Integrated chronic care | Tele-nursing, exercise planning, family screening, and complication surveillance | Remote education, exercise monitoring, autoantibody screening, and multidisciplinary surveillance are reported.[145]C4[162]A1b[163]A1a[220]A1a[319][323] |
| Emerging research | Microbiome, immune, and biomarker-directed approaches | Prebiotic intervention, gut–brain-axis research, ADAM19, IL-6, and oncostatin M remain investigational.[186]A1b[259][318][325] |
Multiglandular Syndromes, Genetic Context and Co-Axis Effects
- ▸Screening for autoimmune thyroid disease and coeliac disease is central to recognising APS in T1DM; additional autoimmune disease may remain under-recognised. [332]
- ▸In women with T1DM planning pregnancy, measure TSH and aim for HbA1c <6.5%; CGM target range is 3.9–10 mmol/L for at least 70% of readings. [217]
- ▸Interpret thyroid tests during DKA cautiously because euthyroid sick syndrome is common enough to require reassessment after recovery. [92]
- ▸Autoantibody-negative childhood diabetes, especially with atypical features, should prompt consideration of monogenic diabetes or another non-autoimmune subtype. [270]
- ▸Insulin resistance, immune-regulatory disorders, Mauriac syndrome and acute kidney injury represent important non-classical co-axes in T1DM. [47][330][331][274][41]
Autoimmune polyendocrine clustering
Type 1 diabetes mellitus (T1DM) commonly coexists with autoimmune thyroid disease (AITD) and coeliac disease, forming part of the autoimmune polyglandular syndrome (APS) spectrum. Current guidance supports screening people with T1DM for thyroid and coeliac disease; however, the optimal evaluation after either disorder is detected remains insufficiently defined. [332] In an adult T1DM cohort with AITD and/or coeliac disease, an extended screening work-up was specifically used to investigate whether additional autoimmune conditions were being missed, highlighting that recognition of APS may be incomplete when assessment stops after the two routinely screened disorders. [332]
The clinical phenotype of associated autoimmune disease may be heterogeneous. Graves’ disease can occur with other autoimmune disorders as part of an APS, and a multicentre retrospective study evaluated whether such autoimmune clustering was associated with greater severity of moderate-to-severe active thyroid eye disease requiring high-dose intravenous corticosteroids. [295]C The presence of thyroid eye disease should therefore be interpreted in the wider autoimmune context rather than as an isolated thyroid complication. [295]C Autoimmune clustering can also extend beyond endocrine organs: nationwide Korean data examined autoimmune thyroid disease and other autoimmune diagnoses during the 10 years preceding myasthenia-gravis diagnosis, supporting the importance of considering temporally dispersed autoimmune comorbidity when neurological or systemic symptoms arise. [282]
Coeliac disease and gastrointestinal–metabolic overlap
Coeliac disease is a relevant associated autoimmune disorder in T1DM and is included in guideline-based screening strategies. [332] A 2025 systematic review and meta-analysis from China assessed coeliac-disease prevalence in high-risk groups, including people with autoimmune disease, gastrointestinal symptoms, irritable bowel syndrome, low body mass index and short stature; the analysis used studies identified through 10 December 2024 and incorporated regional population weighting. [226]A1a These data reinforce the need to interpret chronic gastrointestinal symptoms, poor weight gain, low BMI or unexplained nutritional problems in T1DM as possible coeliac disease rather than attributing them automatically to glycaemic dysregulation. [226]A1a
Thyroid-axis effects and pregnancy
Thyroid testing is particularly important because thyroid dysfunction may alter insulin requirements, glycaemic variability and reproductive risk, although the supplied evidence does not quantify these effects directly. In French expert consensus for pre-existing diabetes, thyroid-stimulating hormone measurement is specifically included in the preconception assessment for women with T1DM. [217]A1c The same consensus recommends preconception HbA1c <6.5% and, for users of continuous glucose monitoring, a glucose target range of 3.9–10 mmol/L (70–180 mg/dL) for at least 70% of readings, together with assessment of microangiopathic and macroangiopathic complications and cardiovascular risk factors. [217]A1c
Acute metabolic illness can transiently distort thyroid testing. In a retrospective cohort of 182 children with T1DM admitted with diabetic ketoacidosis, euthyroid sick syndrome was assessed using TSH, free T4 and free T3 at presentation and again 2 weeks after DKA resolution. [92]B2b Thyroid results obtained during DKA should therefore be interpreted cautiously and, when clinically appropriate, reassessed after recovery rather than immediately diagnosing primary thyroid disease solely from an acute-illness pattern. [92]B2b
Genetic and immune-dysregulation context
Most childhood T1DM is autoimmune, but autoantibody-negative diabetes warrants reconsideration of classification. A Dutch paediatric cohort of 562 patients diagnosed before age 18 compared autoantibody-positive disease—defined using GADA, IA-2A, ZnT8, IAA and/or ICA—with autoantibody-negative disease; anti-ICA-only cases were excluded. [270] The study reported a small subgroup with evidence suggestive of monogenic diabetes, approximately 1.4% of the cohort, demonstrating that a T1DM label does not exclude a genetic form of diabetes. [270] Persistent absence of diabetes-associated autoantibodies, atypical inheritance, syndromic features, unusual insulin requirements or a discordant clinical course should prompt consideration of genetic testing and alternative diabetes subtypes. [270]
Primary immune-regulatory disorders may present with diabetes alongside broader autoimmunity. LRBA deficiency is a primary immunodeficiency within the common-variable-immunodeficiency spectrum and is associated with immune dysregulation, autoimmunity and lymphoproliferation; reported presentations range from isolated autoimmune cytopenias to severe multisystem disease. [47]C4 In a patient with T1DM plus recurrent cytopenias, hypogammaglobulinaemia, lymphoproliferation or unusually extensive autoimmunity, an immune-deficiency syndrome such as LRBA deficiency should be considered in specialist evaluation. [47]C4
Insulin-resistance and body-composition co-axes
Although T1DM is fundamentally an insulin-deficient disorder, insulin resistance can coexist and may contribute to poor metabolic outcomes and microvascular complications. A cross-sectional study of 263 Iraqi adults with T1DM evaluated estimated glucose disposal rate (eGDR) as a validated surrogate of insulin resistance and examined its relationship with metabolic syndrome and microvascular complications. [330] Severe, atypical insulin resistance may rarely reflect a coexisting insulin-signalling disorder: a paediatric case series described four children with Rabson–Mendenhall syndrome, one with type 1A insulin resistance and one with T1DM complicated by severe subcutaneous insulin resistance; all reportedly improved after dapagliflozin treatment. [331]C This was a six-case report series, not evidence for routine SGLT2-inhibitor use in T1DM, and treatment must account for ketoacidosis risk and specialist supervision. [331]C
Finally, recurrent DKA with hepatomegaly may indicate a complication of inadequate insulin delivery rather than a new endocrine gland disorder. A 14-year-old with longstanding T1DM, irregular meals, inconsistent glucose monitoring, poor insulin adherence and recurrent DKA was reported with Mauriac syndrome. [274]C Polyuria in T1DM also requires attention to kidney injury: a systematic review identified 32 paediatric patients with polyuria, including cases with DKA and new-onset T1DM without DKA, illustrating that acute kidney injury can complicate these presentations. [41]C4
| Context | Evidence-informed implication |
|---|---|
| AITD and/or coeliac disease | Consider APS and assess for additional autoimmune disease when clinically indicated. [332] |
| Pregnancy planning | TSH assessment; HbA1c <6.5%; CGM 3.9–10 mmol/L for ≥70% of readings. [217]A1c |
| DKA | Thyroid abnormalities may represent euthyroid sick syndrome; reassess after resolution. [92]B2b |
| Autoantibody-negative diabetes | Consider monogenic or alternative diabetes classification. [270] |
| Severe insulin resistance | Evaluate for insulin-signalling disorders; dapagliflozin evidence is limited to a six-case series. [331]C |
| Recurrent DKA with hepatomegaly | Consider Mauriac syndrome, particularly with poor adherence and irregular nutrition. [274]C |
Complications and Long-term Sequelae
- ▸DKA is a potentially life-threatening complication, and intentional insulin omission is associated with DKA, microvascular complications, and increased mortality [74].
- ▸CVD remains a major long-term complication; smoking, diet, physical activity, BMI, alcohol use, and sleep were evaluated as modifiable lifestyle factors in a prospective T1D cohort [334].
- ▸Dyslipidemia is an important cardiovascular risk factor in youth with T1D, while omega-3 supplementation evidence was still being quantified for lipid and glycemic outcomes [234][333].
- ▸T1D is associated with additional autoimmune disease in children and adolescents and may contribute to osteoporosis risk through metabolic mediators [284][335].
- ▸Psychological burden, diabetes burnout, fear of complications, and intentional insulin omission require active clinical recognition [74][310].
- ▸Exercise perception may reflect cardiovascular strain but does not reliably predict the glycemic response; glucose monitoring remains necessary [162].
- ▸CGM and automated insulin delivery are important technologies, but evidence and feasibility vary by clinical setting, including advanced kidney disease and hospitalization [306][338][309].
Overview
Type 1 diabetes mellitus (T1D) produces acute metabolic emergencies, chronic microvascular and macrovascular injury, treatment-related harms, psychosocial burden, and comorbid autoimmune disease. The available updated evidence includes systematic reviews, cohort studies, clinical trials, cross-sectional analyses, case reports, and experimental work; therefore, findings differ in certainty and many studies are associative rather than causal.
Acute metabolic and infectious complications
Diabetic ketoacidosis (DKA) remains a potentially life-threatening complication of insulin deficiency. Intentional insulin omission—often termed “diabulimia”—is particularly reported in adolescents and young adults and is associated with DKA, microvascular complications, and increased mortality. The condition may be missed because of stigma, diagnostic ambiguity, and overlap with routine diabetes self-management [74]D5. A systematic review of immune checkpoint inhibitor-associated T1D identified this condition as a rare but potentially life-threatening endocrine immune-related adverse event and evaluated its incidence, risk factors, DKA occurrence, and prognostic implications in adults receiving cancer immunotherapy [303].
Severe hyperglycemia and DKA may predispose to invasive infection. A reported adolescent case developed rhino-orbital-cerebral mucormycosis after DKA; this infection can progress rapidly and cause substantial disability or death, although the report cannot establish incidence or general risk [293]C. Experimental evidence also indicates that diabetes may worsen postoperative infection and wound-healing outcomes: in a murine spinal-implant model, both T1D and T2D were compared with nondiabetic controls for infectious burden, inflammatory response, wound healing, and response to semaglutide. These findings are preclinical and should not be directly extrapolated to clinical treatment [261].
Cardiovascular and cerebrovascular disease
Cardiovascular disease (CVD) is a major long-term complication of T1D [334]. In a prospective UK Biobank cohort of individuals with T1D free of CVD at baseline, smoking, alcohol consumption, body-mass index, diet quality, physical activity, and sleep duration were combined into a healthy-lifestyle score to examine incident CVD [334]. Adult-onset T1D was also evaluated against propensity-matched T2D in a multicenter U.S. database, with follow-up through 2025 and assessment of 10-year major adverse cardiovascular and cerebrovascular events, including stroke, hemorrhage, cardiac arrest, heart failure, myocardial infarction, and peripheral vascular events [285]C.
Dyslipidemia is an important modifiable cardiovascular risk factor in youth with T1D. In an Australian pediatric audit, 78% of 335 patients followed initial lipid-screening guidance, while testing occurred at a mean interval of 17 months rather than the recommended five-year interval; the study also examined dyslipidemia trajectories and subsequent management [234]C4. A 2026 systematic review and meta-analysis evaluated whether omega-3 polyunsaturated fatty-acid supplementation changes total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, fasting plasma glucose, or HbA1c in T1D. The abstract establishes these prespecified outcomes but does not provide the pooled estimates; supplementation should therefore not be presented as proven to prevent cardiovascular or glycemic complications on the basis of this citation alone [333]. Adolescents with T1D have also been studied using the triglyceride-glucose index and phase angle as potential markers of glycemic control, body composition, and cardiovascular risk, but the available evidence is cross-sectional [236]C4. Platelet indices, adiponectin, leptin, and C-reactive protein were similarly investigated in adults with long-standing T1D because of possible links with inflammation and cardiovascular risk; these findings are exploratory and associative [337].
Renal, ocular, neurologic, skeletal, and reproductive sequelae
Long-standing T1D may coexist with advanced kidney disease and dialysis dependence. A case report described automated insulin delivery in a woman with T1D, peritoneal dialysis, visual impairment, and multiple diabetes-associated complications, suggesting feasibility in a highly complex setting but providing no generalizable efficacy estimate [338]C. Simultaneous pancreas-kidney transplantation remains an established treatment option for selected patients with diabetes and end-stage renal disease; a single-center case series of 11 recipients examined a six-phase intraoperative glycemic-control algorithm and immediate outcomes, but its small size limits inference [305]C.
Osteoporosis is another recognized concern. Mendelian-randomization analyses investigated the causal relationship between T1D and osteoporosis and assessed BMI, HbA1c, medium very-low-density-lipoprotein cholesterol, saturated fatty acids, and sex hormone-binding globulin as potential mediators [335]. The cited study supports investigation of metabolic pathways but does not by itself define screening or treatment thresholds.
In postmenopausal women with T1D, a BETTER registry analysis compared retinopathy, neuropathy, CVD, falls, HbA1c, insulin dose, hypoglycemia, depressive symptoms, and fear of hypoglycemia between 121 premenopausal and 90 postmenopausal participants aged 40–60 years. Because this was cross-sectional, differences cannot establish that menopause caused any complication [336].
Autoimmune comorbidity
Children and adolescents with T1D have increased susceptibility to additional autoimmune disease. A retrospective tertiary-center cohort followed 639 young people diagnosed between 2004 and 2018 and evaluated the prevalence, spectrum, timing, and clinical characteristics of autoimmune conditions, together with associated autoantibodies [284].
Psychosocial and behavioral sequelae
Psychological burden is itself a clinically important long-term consequence. In Polish MyDiaMate users, the most frequently endorsed concerns were future complications (85.1%), guilt or worry when diabetes was out of control (79.2%), diabetes burnout (72.3%), and feeling that diabetes controls one’s life (72.3%). Network and intervention modeling identified a densely connected burden domain, but the exploratory sample consisted of 101 active users and cannot establish treatment effectiveness [310]. Intentional insulin omission requires assessment for eating-disorder psychopathology as well as urgent metabolic risk [74]D5.
Exercise, monitoring, and hospitalization-related outcomes
In a randomized crossover trial, 12 adults with T1D completed approximately 30-minute aerobic-interval and resistance-training sessions. Post-session perceived exertion was associated with cardiovascular strain but not with the glycemic response, indicating that perceived exertion may help characterize cardiovascular load but cannot replace glucose monitoring [162]A1b. Evidence for the optimal timing, frequency, and glycemic targets of self-monitoring of blood glucose in adults remains limited and inconsistent according to a Cochrane review [273]. Continuous glucose monitoring has been reviewed for clinical outcomes, costs, and technological limitations across major commercial platforms, reflecting its central role in reducing persistent gaps in diabetes management while acknowledging implementation constraints [306]. Among adults aged ≥18 years hospitalized with T1D, a 2022 Nationwide Readmissions Database analysis evaluated the association of insulin-delivery modality with 30-day readmission and in-hospital mortality; its retrospective design limits causal interpretation [309].
| Domain | Updated evidence | Interpretation |
|---|---|---|
| Acute metabolic | DKA and intentional insulin omission; ICI-associated T1D may include DKA [74]D5[303] | High clinical urgency; incidence and prognosis vary by context |
| Cardiovascular | Lifestyle, dyslipidemia, MACCE, lipid biomarkers, and omega-3 outcomes studied [234]C4[236]C4[285]C[333][334][337] | Risk is multifactorial; several studies are observational |
| Renal and transplant-related | Peritoneal dialysis case report and pancreas-kidney transplantation case series [305]C[338]C | Feasibility evidence, not definitive comparative efficacy |
| Skeletal | T1D–osteoporosis relationship and potential mediators assessed by Mendelian randomization [335] | Causal pathways remain under study |
| Autoimmune | Additional autoimmune diseases assessed in 639 pediatric patients [284] | Long-term surveillance is clinically relevant |
| Psychosocial | Burnout, worry, fear of complications, and insulin omission documented [74]D5[310] | Requires integrated behavioral and diabetes care |
| Monitoring and exercise | SMBG evidence remains uncertain; CGM and exertion-based assessment reviewed [162]A1b[273][306] | Technology and monitoring should be individualized |
Prognosis, Natural History, Special Populations and Prevention
- ▸CGM may improve diabetes-management outcomes, but cost, access, and platform limitations remain relevant [306].
- ▸Hospitalized children with newly diagnosed T1DM should be monitored for hypoglycemia below **3.9 mmol/L**, including grade 2 values below **3.0 mmol/L** [343].
- ▸Long-term cardiovascular risk in adult-onset T1DM has been evaluated against propensity-matched type 2 diabetes cohorts using 10-year MACCE outcomes [285].
- ▸Additional autoimmune disease, especially celiac disease, is an important feature of pediatric T1DM follow-up [284][292][345].
- ▸ICI-T1DM is rare but potentially life-threatening and may present with diabetic ketoacidosis [303].
- ▸BCG vaccination and vitamin supplementation remain investigational for T1DM prevention [312][342].
- ▸Autoantibody screening of first-degree relatives can identify immune risk but should include counseling about anxiety and uncertain progression [145].
- ▸A positive disordered-eating screen is defined by a DEPS-R score of **≥20** in the cited Spanish study [339].
Natural history and prognosis
Type 1 diabetes mellitus (T1DM) is characterized by autoimmune destruction of pancreatic β-cells and lifelong dependence on exogenous insulin; the clinical course includes risks related to glycemic variability, hypoglycemia, chronic microvascular disease, cardiovascular disease, and associated autoimmunity [306]. Continuous glucose monitoring (CGM) is increasingly used to improve glucose surveillance and diabetes-management outcomes, although the available evidence also identifies cost, access, and platform-related limitations [306]. In children and adolescents newly diagnosed with T1DM, hypoglycemia may occur during initial hospitalization; a Chinese retrospective cohort of 567 patients evaluated glucose values below 3.9 mmol/L, distinguishing grade 1 hypoglycemia at 3.0–3.9 mmol/L from grade 2 hypoglycemia below 3.0 mmol/L, and investigated associated clinical factors [343].
Long-term vascular prognosis is particularly important in adult-onset disease. In a propensity-matched U.S. database cohort, adults diagnosed with T1DM or type 2 diabetes between 2005 and 2015 were followed through 2025 and compared for 10-year major adverse cardiovascular and cerebrovascular events, including stroke, hemorrhage, cardiac arrest, heart failure, myocardial infarction, and peripheral vascular events [285]C. The study specifically stratified participants by age, HbA1c, and use of non-insulin antihyperglycemic agents, providing comparative evidence on long-term risk but not establishing that these factors independently determine prognosis [285]C.
Diabetic kidney disease remains a major prognostic concern. Urinary microalbuminuria is described as the current standard for diagnosis and staging, but it may reflect established renal injury rather than the earliest tubular abnormalities [288]. In a case-control study of 90 children, urinary fatty acid-binding protein 1 (FABP1) was investigated as a potential marker of proximal-tubular injury in T1DM with and without diabetic kidney disease; its clinical prognostic value requires confirmation beyond this single-center study [288]. A separate case report described proliferative glomerulonephritis with monoclonal IgG1-κ deposits in a woman with a 19-year history of T1DM and poor glycemic control, emphasizing that new edema, proteinuria, renal insufficiency, or systemic symptoms should not automatically be attributed to diabetic nephropathy [93]C4.
Autoimmune comorbidity and special populations
Children and adolescents with T1DM are at increased risk of additional autoimmune diseases [284]. In a retrospective cohort of 639 pediatric patients followed at a tertiary endocrinology center, investigators evaluated the prevalence, spectrum, timing, clinical characteristics, and associated factors of autoimmune comorbidities using clinical and autoantibody data [284]. Celiac disease is a prominent associated condition: a retrospective Algerian study of 109 children and adolescents examined the relationship between age at T1DM diagnosis and subsequent celiac disease, including age at diagnosis, serology, histopathology, and HbA1c [345]C. Pediatric celiac disease cohorts likewise document coexisting immune-mediated conditions, supporting continued attention to autoimmune clustering in affected children [292]C.
Autoimmune neurologic disease is uncommon but clinically significant. GAD65 antibodies occur in T1DM and other autoimmune diseases, including autoimmune thyroid disease and pernicious anemia, but may also be associated with autoimmune encephalitis and epilepsy; a pediatric case series and literature review described three children or young adults with GAD65-associated neurologic disease [344]. These observations support evaluation of atypical neurologic symptoms rather than assuming that GAD65 positivity is solely a diabetes marker [344].
Obesity is increasingly relevant in pediatric T1DM. A systematic review evaluated the bidirectional relationship between childhood obesity and T1DM risk, post-diagnostic weight trajectories, and metabolic outcomes, reflecting the coexistence of rising childhood obesity prevalence and T1DM incidence [135]B2a. In youth with T1DM, dyslipidemia is another modifiable cardiovascular risk factor. An Australian audit of 335 pediatric patients assessed adherence to lipid-screening guidance, testing intervals, dyslipidemia trajectories, and subsequent management; mean testing intervals exceeded the recommended 5-year interval in the reported clinical setting [234]C4.
Treatment-related and transplant populations
Immune checkpoint inhibitor-induced T1DM (ICI-T1DM) is a rare, potentially life-threatening endocrine immune-related adverse event in adult cancer patients treated with immune checkpoint inhibitors [303]. A systematic review and meta-analysis evaluated pooled incidence, diabetic ketoacidosis occurrence, risk associated with dual versus monotherapy exposure, pre-existing diabetes, and prognostic outcomes using odds and hazard ratios [303]. Patients receiving immune checkpoint inhibitors therefore require awareness of abrupt insulin deficiency and possible DKA, although the abstract does not provide pooled estimates [303].
For selected patients with T1DM and end-stage renal disease, simultaneous pancreas-kidney transplantation can provide metabolic stabilization and improved survival [305]C. A single-center case series of 11 patients with T1DM or type 2 diabetes and end-stage renal disease evaluated a six-phase intraoperative glycemic-control algorithm, illustrating the importance of phase-specific glucose management for graft viability while providing limited generalizable outcome evidence [305]C.
Prevention and risk reduction
No preventive intervention can be recommended from these references as definitively preventing ordinary autoimmune T1DM. BCG vaccination has been studied as an adjunctive or preventive strategy because of proposed immunometabolic effects; a systematic review found both supportive and opposing evidence, with some interventional and mechanistic studies reporting changes in C-peptide, HbA1c, β-cell recovery, and immune modulation through tumor-necrosis-factor induction [312]. The review therefore supports continued investigation, not routine BCG use for T1DM prevention [312].
Vitamin A and vitamin D were investigated in a small retrospective pediatric study including 31 children with T1DM and 31 controls; although these nutrients have immunoregulatory roles, the study design and sample size do not establish that supplementation prevents T1DM [342]. Autoantibody screening may identify risk in first-degree relatives. A Turkish multicenter study screened 440 relatives aged 2–18 years for ZnT8, GAD, insulin, and IA-2 autoantibodies and also assessed anxiety after result disclosure in an older subsample, highlighting the need to pair screening with appropriate counseling [145]C4.
Seasonality may modify presentation rather than provide a practical prevention strategy. A 40-year cohort of 2,954 patients diagnosed between 1981 and 2024 found age- and immunity-dependent seasonal patterns, with no seasonal fluctuation in early-onset T1DM, suggesting stronger genetic or immunologic influences in that group [341]. In adults with established T1DM, disordered eating behaviors are an additional preventable source of harm: a Spanish cross-sectional study of 451 people aged ≥16 years used the Diabetes Eating Problems Survey-Revised, with a score of ≥20 indicating a positive screen [339]. Early psychosocial screening and multidisciplinary support are therefore relevant components of risk reduction, although the cross-sectional design cannot prove causality [339].
| Domain | Evidence-based consideration |
|---|---|
| Glycemic safety | Monitor for hypoglycemia below 3.9 mmol/L in newly diagnosed hospitalized children [343]. |
| Cardiovascular prognosis | Adult-onset T1DM has been compared with matched type 2 diabetes for 10-year MACCE risk [285]C. |
| Kidney disease | Microalbuminuria remains standard; FABP1 is investigational for earlier tubular injury [288]. |
| Autoimmunity | Assess for associated autoimmune disease, particularly celiac disease, in pediatric T1DM [284][292]C[345]C. |
| ICI-related diabetes | Recognize abrupt insulin deficiency and possible DKA during immune checkpoint inhibitor therapy [303]. |
| Prevention | BCG and vitamin A/D interventions are not established preventive treatments [312][342]. |
| Family screening | Autoantibody screening is feasible in first-degree relatives but requires counseling [145]C4. |
| Psychosocial risk | Screen for disordered eating; DEPS-R ≥20 was positive in the cited study [339]. |
References
- [1]
Dost A, Bechtold S, Fink K et al.. “2017 American Academy of Pediatrics Clinical Practice Guideline: Impact on Prevalence of Arterial Hypertension in Children and Adolescents With Type 1 Diabetes.” Diabetes care (2020). PMID: 32229598 ↗
L2GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [2]
de Vries M, Westerink J, Kaasjager KHAH et al.. “Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32827432 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [3]
Wada E, Onoue T, Kinoshita T et al.. “Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study.” Diabetologia (2021). PMID: 34268631 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation - [4]
Shaka H, Aguilera M, Aucar M et al.. “Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34043791 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [5]
Amato MC, Guarnotta V, Ciresi A et al.. “No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24243639 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [6]
Codner E, Soto N, Lopez P et al.. “Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16569737 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [7]
Leslie RD, Palmer J, Schloot NC et al.. “Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.” Diabetologia (2016). PMID: 26498592 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [8]
Marques-Couto P, Afonso J, Coelho-Costa I et al.. “Prevalence and Risk Factors of Diabetic Macular Edema in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Ophthalmology. Retina (2025). PMID: 41016555 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature - [9]
Weissmann S, Amitai N, Honig E et al.. “Maternal type 1 diabetes mellitus and atopic dermatitis in offspring: A nationwide cohort study.” JAAD international (2026). PMID: 42100114 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [10]
Kim KJ, Kim S, Oh R et al.. “High Waist-to-Height Ratio Increases the Risk of Cardiovascular Outcomes in Adults with Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2025). PMID: 40904015 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [11]
Weng SS, Chien LY. “IVF and risk of Type 1 diabetes mellitus: a population-based nested case-control study.” Human reproduction (Oxford, England) (2024). PMID: 38852062 ↗
L3CASE_CONTROLCited in: Definition, Classification and Axis Nomenclature - [12]
Tetik Dinçer B, Urgancı N, Koç A et al.. “Association of endocrine autoantibodies (anti-TPO, anti-GAD, anti-insulin) with histopathological severity in pediatric Celiac disease: a retrospective cohort study.” BMC pediatrics (2025). PMID: 41430660 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [13]
Zan Y, Wei Y, Zhang W et al.. “Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review.” Medicine (2025). PMID: 40388765 ↗
L4SR_OBSCited in: Definition, Classification and Axis Nomenclature - [14]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652453 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [15]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” European journal of endocrinology (2025). PMID: 40652450 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [16]
Pozzilli P, Bosi E, Cirkel D et al.. “Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32219329 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment - [17]
Pescovitz MD, Greenbaum CJ, Bundy B et al.. “B-lymphocyte depletion with rituximab and β-cell function: two-year results.” Diabetes care (2013). PMID: 24026563 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [18]
Codner E, Escobar-Morreale HF. “Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17284617 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [19]
Du M, Basu A, Fu D et al.. “Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study.” Diabetes care (2013). PMID: 23393212 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [20]
de Filette JMK, Pen JJ, Decoster L et al.. “Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.” European journal of endocrinology (2019). PMID: 31330498 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [21]
Geddes J, Deary IJ, Frier BM. “Effects of acute insulin-induced hypoglycaemia on psychomotor function: people with type 1 diabetes are less affected than non-diabetic adults.” Diabetologia (2008). PMID: 18709352 ↗
L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies - [22]
Clotman K, Janssens K, Specenier P et al.. “Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29955867 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [23]
Morkos M, Nensey NK, Bindal A. “Micafungin-Induced Hypoglycemia in a Patient With Type 1 Diabetes: A Case Report and Review of Literature.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398618 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [24]
Yoneda S, Imagawa A, Fukui K et al.. “A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28398495 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [25]
Fazeli PK, Horowitz MC, MacDougald OA et al.. “Marrow fat and bone--new perspectives.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23393168 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [26]
Tomar N, Gupta N, Goswami R. “Calcium-sensing receptor autoantibodies and idiopathic hypoparathyroidism.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23873991 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [27]
Hough FS, Pierroz DD, Cooper C et al.. “MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus.” European journal of endocrinology (2015). PMID: 26537861 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [28]
Verrotti A, Scaparrotta A, Olivieri C et al.. “Seizures and type 1 diabetes mellitus: current state of knowledge.” European journal of endocrinology (2012). PMID: 22956556 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [29]
Kratzsch J, Knerr I, Galler A et al.. “Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor.” European journal of endocrinology (2006). PMID: 16990661 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [30]
Assmann TS, Brondani Lde A, Bauer AC et al.. “Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus.” European journal of endocrinology (2014). PMID: 24408902 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [31]
Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [32]
Frandsen CS, Dejgaard TF, Madsbad S. “Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.” The lancet. Diabetes & endocrinology (2016). PMID: 26969516 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [33]
Elliott J, Sloan G, Stevens L et al.. “Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study.” Diabetologia (2023). PMID: 37870649 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [34]
Korczak DJ, Pereira S, Koulajian K et al.. “Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link.” Diabetologia (2011). PMID: 21789690 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification - [35]
Pane JA, Coulson BS. “Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes.” Diabetologia (2015). PMID: 25794781 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [36]
Roca-Rivada A, Marín-Cañas S, Colli ML et al.. “Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death.” Diabetologia (2023). PMID: 36988639 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [37]
Nieuwdorp M, Holleman F, de Groot E et al.. “Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis.” Diabetologia (2007). PMID: 17415544 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae - [38]
Segev Y, Eshet R, Yakir O et al.. “Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.” Diabetologia (2007). PMID: 17443310 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [39]
Kateel R, Parida A, Chogtu B et al.. “Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42105869 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies - [40]
Abdel-Rahman SM, Al-Shiab R, Shah E et al.. “Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.” Diabetes, obesity & metabolism (2026). PMID: 41605813 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [41]
Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [42]
Jawad M, Afaq S, Hussain S et al.. “Effect of digital interventions on adherence to the management of type 1 diabetes mellitus patients: a systematic review.” BMC endocrine disorders (2025). PMID: 41462455 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [43]
Chen Y, Tang Y, Yue R et al.. “Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41331723 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [44]
Biondi B, Kahaly GJ, Robertson RP. “Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.” Endocrine reviews (2019). PMID: 30649221 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [45]
Meijnikman AS, Gerdes VE, Nieuwdorp M et al.. “Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.” Endocrine reviews (2018). PMID: 29309555 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [46]
Rotondi M, Chiovato L, Romagnani S et al.. “Role of chemokines in endocrine autoimmune diseases.” Endocrine reviews (2007). PMID: 17475924 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [47]
Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [48]
Al Hayek A, Robert AA, Al Burayk AK et al.. “Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia.” Current diabetes reviews (2026). PMID: 41691684 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [49]
Horton WB, Snell-Bergeon JK. “Hemoglobin A1c Variability Metrics Predict Coronary Artery Calcium and Cardiovascular Events in Type 1 Diabetes: The CACTI Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36637994 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [50]
Tsaitlin-Mor L, Cahen-Peretz A, Bentov Y et al.. “Long-term Risk for Type 1 Diabetes and Obesity in Early Term Born Offspring: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38079466 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [51]
Balsells M, García-Patterson A, Gich I et al.. “Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19808847 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [52]
Nicholson WK, Robinson KA, Smallridge RC et al.. “Prevalence of postpartum thyroid dysfunction: a quantitative review.” Thyroid : official journal of the American Thyroid Association (2006). PMID: 16839259 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [53]
Aslam AA, Baksh RA, Pape SE et al.. “Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records.” Diabetes care (2022). PMID: 36178378 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [54]
Zhong VW, Juhaeri J, Cole SR et al.. “Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2017). PMID: 28716781 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [55]
Drenthen LCA, Ajie M, Abbink EJ et al.. “No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study.” Diabetologia (2023). PMID: 36879098 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [56]
Bo S, Gentile L, Castiglione A et al.. “C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.” European journal of endocrinology (2012). PMID: 22577110 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [57]
Morgan E, Halliday SR, Campbell GR et al.. “Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2015). PMID: 26564178 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [58]
de Vries SAG, Verheugt CL, Mul D et al.. “Do sex differences in paediatric type 1 diabetes care exist? A systematic review.” Diabetologia (2023). PMID: 36700969 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [59]
Jeitler K, Horvath K, Berghold A et al.. “Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.” Diabetologia (2008). PMID: 18351320 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [60]
Cardwell CR, Stene LC, Joner G et al.. “Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2008). PMID: 18292986 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [61]
Stagnaro-Green A. “Approach to the patient with postpartum thyroiditis.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22312089 ↗
L5CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [62]
Chou IC, Wang CH, Lin WD et al.. “Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study.” Diabetologia (2016). PMID: 27030312 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [63]
Dafoulas GE, Toulis KA, Mccorry D et al.. “Type 1 diabetes mellitus and risk of incident epilepsy: a population-based, open-cohort study.” Diabetologia (2016). PMID: 27796422 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [64]
Mikłosz A, Chabowski A. “Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36916961 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [65]
Li FR, Hukportie DN, Yang J et al.. “Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes.” Diabetes care (2022). PMID: 35944243 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [66]
Chen X, Affinati AH, Lee Y et al.. “Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.” Diabetes care (2022). PMID: 35238899 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [67]
Jacobson AM, Braffett BH, Erus G et al.. “Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study.” Diabetes care (2022). PMID: 35699949 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae - [68]
Tamer G, Arik S, Tamer I et al.. “Relative vitamin D insufficiency in Hashimoto's thyroiditis.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21751884 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors - [69]
Denzer C, Karges B, Näke A et al.. “Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus.” European journal of endocrinology (2013). PMID: 23384709 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [70]
Sahakyan K, Klein BE, Lee KE et al.. “Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus.” European journal of endocrinology (2010). PMID: 20332124 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [71]
Chantzichristos D, Persson A, Eliasson B et al.. “Incidence, prevalence and seasonal onset variation of Addison's disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies.” European journal of endocrinology (2017). PMID: 29066573 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [72]
Okosieme OE, Wijeyaratne CN, Lazarus JH et al.. “Restricted thyroglobulin antibody epitope specificities in subjects with type 1 diabetes mellitus.” European journal of endocrinology (2009). PMID: 19561043 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors - [73]
Pappa A, Koromantzos P, Seremidi K et al.. “Dental caries and periodontal status in children and adolescents with type 1 diabetes mellitus: an umbrella review.” European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry (2026). PMID: 42270944 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [74]
Anesini MB, Pinto M, Bellezza M et al.. “Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123251 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [75]
Shao MM, Scheideman AF, Zhou AM et al.. “Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987896 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [76]
Di Gialleonardo V, de Vries EF, Di Girolamo M et al.. “Imaging of β-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus.” Endocrine reviews (2012). PMID: 22889646 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [77]
Mackay L, Kilbride L, Adamson KA et al.. “Hormone replacement therapy for women with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23744560 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [78]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2013). PMID: 23543528 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [79]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2006). PMID: 17054193 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [80]
Callaghan BC, Little AA, Feldman EL et al.. “Enhanced glucose control for preventing and treating diabetic neuropathy.” The Cochrane database of systematic reviews (2012). PMID: 22696371 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [81]
Montero N, Webster AC, Royuela A et al.. “Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.” The Cochrane database of systematic reviews (2014). PMID: 25220222 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [82]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [83]
Singh M, Subramanian A, Wambua S et al.. “Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.” BMC medicine (2026). PMID: 42169116 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [84]
Gatira DN, Getnet M, Liyew B et al.. “Incidence and predictors of diabetic ketoacidosis among adults with type 1 diabetes in Northwest, Ethiopia, 2023: a retrospective cohort study.” BMC public health (2026). PMID: 41957727 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae - [85]
Halpern B, Nery M, Pereira MAA. “Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immunodeficiency.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29846625 ↗
L4CASE_REPORTCited in: Clinical Presentation - [86]
Aly HH, Fouda EM, Kotby AA et al.. “COVID-19-Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series.” Diabetes care (2022). PMID: 35113159 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [87]
Dunn A, Lam A, Hidalgo L et al.. “Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398662 ↗
L4OTHERCited in: Clinical Presentation - [88]
Schreiner F, Plamper M, Dueker G et al.. “Infancy-Onset T1DM, Short Stature, and Severe Immunodysregulation in Two Siblings With a Homozygous LRBA Mutation.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26745254 ↗
L4OTHERCited in: Clinical Presentation - [89]
Johnson SR, Carter HE, Leo P et al.. “Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.” Diabetes care (2018). PMID: 30523035 ↗
L2OTHERCited in: Clinical Presentation, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [90]
Tsai EB, Sherry NA, Palmer JP et al.. “The rise and fall of insulin secretion in type 1 diabetes mellitus.” Diabetologia (2006). PMID: 16404554 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [91]
Aparna KV, Darshan M, Kulkarni A et al.. “Emphysematous pyelonephritis in children: Lessons from a case report and systematic review.” Journal of pediatric urology (2026). PMID: 42285016 ↗
L4SR_OBSCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [92]
Alqahtani YA, Shati AA, Alshaikh AA et al.. “Prevalence and Recovery of Euthyroid Sick Syndrome in Pediatric Diabetic Ketoacidosis: A Retrospective Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 41749652 ↗
L2COHORTCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [93]
Li X, Zhang X, Dai X et al.. “Proliferative glomerulonephritis with monoclonal immunoglobulin IgG1-κ deposition in a patient with type 1 diabetes: a case report and literature review.” Frontiers in medicine (2026). PMID: 42375207 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [94]
Bai H, Yu J, Wang T et al.. “Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.” Frontiers in endocrinology (2026). PMID: 42137361 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [95]
Liu S, Cao C, Wang X. “Autoimmune polyglandular syndrome type 1 with compound heterozygous AIRE gene pathogenic variants and stage 1 type 1 diabetes mellitus: case report and literature review of Chinese population.” Frontiers in immunology (2026). PMID: 41993177 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment - [96]
Valdivia Camacho OD, Allison T, Wilson LB et al.. “Pediatric Cataracts as a Presenting Sign of Type 1 Diabetes Mellitus.” The Journal of pediatrics (2025). PMID: 40945580 ↗
L4CASE_REPORTCited in: Clinical Presentation - [97]
Maruyama T, Tanaka S, Shimada A et al.. “Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18397986 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [98]
Matejko B, Juza A, Kieć-Wilk B et al.. “Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.” Diabetes care (2022). PMID: 35972259 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [99]
Luijf YM, DeVries JH, Zwinderman K et al.. “Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management.” Diabetes care (2013). PMID: 24170747 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [100]
Ma X, Xie Z, Qin J et al.. “Association of Vitamin D Pathway Gene CYP27B1 and CYP2R1 Polymorphisms with Autoimmune Endocrine Disorders: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32915988 ↗
L3SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [101]
Ludvigsson J, Faresjö M, Hjorth M et al.. “GAD treatment and insulin secretion in recent-onset type 1 diabetes.” The New England journal of medicine (2008). PMID: 18843118 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [102]
Tamborlane WV, Beck RW, Bode BW et al.. “Continuous glucose monitoring and intensive treatment of type 1 diabetes.” The New England journal of medicine (2008). PMID: 18779236 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [103]
Ludvigsson J, Krisky D, Casas R et al.. “GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.” The New England journal of medicine (2012). PMID: 22296077 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [104]
Zhong VW, Juhaeri J, Mayer-Davis EJ. “Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2018). PMID: 29386248 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [105]
Szypowska A, Ramotowska A, Dzygalo K et al.. “Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials.” European journal of endocrinology (2011). PMID: 22096111 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [106]
Teo E, Hassan N, Tam W et al.. “Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.” Diabetologia (2022). PMID: 35141761 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [107]
Orban T, Bundy B, Becker DJ et al.. “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2011). PMID: 21719096 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [108]
Schultz ANØ, Christensen R, Bollig G et al.. “Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial.” Diabetologia (2025). PMID: 41198916 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [109]
Benhalima K, van Nes F, Laenen A et al.. “Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.” Diabetologia (2021). PMID: 34647140 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [110]
Gejl M, Gjedde A, Brock B et al.. “Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial.” Diabetologia (2017). PMID: 29188338 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [111]
Golicki DT, Golicka D, Groele L et al.. “Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2007). PMID: 18060380 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [112]
Goldacre RR. “Associations between birthweight, gestational age at birth and subsequent type 1 diabetes in children under 12: a retrospective cohort study in England, 1998-2012.” Diabetologia (2017). PMID: 29128935 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [113]
De Meulemeester J, Keymeulen B, De Block C et al.. “One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.” Diabetologia (2025). PMID: 39934368 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [114]
Yapanis M, James S, Craig ME et al.. “Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35094087 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [115]
Shalimova A, Graff B, Gąsecki D et al.. “Cognitive Dysfunction in Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30657922 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [116]
Prinz N, Tittel SR, Bachran R et al.. “Characteristics of Patients with Type 1 Diabetes and Additional Autoimmune Disease in the DPV Registry.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34061946 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [117]
Wang Y, Qin Y, Gu H et al.. “High Residual β-cell Function in Chinese Patients With Autoimmune Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35218654 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [118]
Menon JC, Singh P, Archana A et al.. “High Frequency of Recessive WFS1 Mutations Among Indian Children With Islet Antibody-negative Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37931151 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [119]
Ling P, Yang D, Wang C et al.. “Basal Hyperglycemia Contributes More Than 50% to Time in Range in Pregnant Women With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38686666 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [120]
Demmer RT, Holtfreter B, Desvarieux M et al.. “The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP).” Diabetes care (2012). PMID: 22855731 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [121]
Barrett CE, Park J, Kompaniyets L et al.. “Intensive Care Unit Admission, Mechanical Ventilation, and Mortality Among Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S.” Diabetes care (2021). PMID: 34158365 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [122]
Epstein EJ, Osman JL, Cohen HW et al.. “Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes.” Diabetes care (2013). PMID: 23596179 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [123]
Scheuing N, Bartus B, Berger G et al.. “Clinical characteristics and outcome of 467 patients with a clinically recognized eating disorder identified among 52,215 patients with type 1 diabetes: a multicenter german/austrian study.” Diabetes care (2014). PMID: 24623022 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [124]
van Elderen SG, Brandts A, van der Grond J et al.. “Cerebral perfusion and aortic stiffness are independent predictors of white matter brain atrophy in type 1 diabetic patients assessed with magnetic resonance imaging.” Diabetes care (2011). PMID: 21216862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [125]
Lundgaard AT, Westergaard D, Röder T et al.. “Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case-control study.” Diabetologia (2024). PMID: 39078488 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [126]
Aleksova J, Ebeling PR, Milat F et al.. “DXA-derived advanced hip analysis and the trabecular bone score in end-stage kidney disease secondary to type 1 diabetes.” European journal of endocrinology (2022). PMID: 36315195 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [127]
Martos-Moreno GA, Barrios V, Soriano-Guillén L et al.. “Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy.” European journal of endocrinology (2006). PMID: 17062893 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [128]
Faccinetti NI, Guerra LL, Penas Steinhardt A et al.. “Characterization of zinc transporter 8 (ZnT8) antibodies in autoimmune diabetic patients from Argentinian population using monomeric, homodimeric, and heterodimeric ZnT8 antigen variants.” European journal of endocrinology (2015). PMID: 26567119 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [129]
Rogowicz-Frontczak A, Zozuliłska-Ziołkiewicz D, Litwinowicz M et al.. “Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes?” European journal of endocrinology (2014). PMID: 24480135 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [130]
Krassas GE, Tziomalos K, Pontikides N et al.. “Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population.” European journal of endocrinology (2007). PMID: 17535862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [131]
Lin Q, Zhou Y, Lei M et al.. “Efficacy and safety of automated insulin delivery system in very young children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42108409 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [132]
Murray JA, Husby S. “Celiac Disease.” The New England journal of medicine (2026). PMID: 41950475 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [133]
Langendam M, Luijf YM, Hooft L et al.. “Continuous glucose monitoring systems for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22258980 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [134]
Clar C, Waugh N, Thomas S. “Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17443539 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [135]
Mărgineanu C, Usatiuc LO, Sur ML et al.. “The Bidirectional Relationship Between Type 1 Diabetes Mellitus and Obesity in Pediatric Patients: A Systematic Review.” Children (Basel, Switzerland) (2026). PMID: 42353914 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [136]
Ma IH, Huang WL, Liu YL et al.. “Early Retinal Changes Detected Using Optical Coherence Tomography Angiography in Youth with Type 1 Diabetes Mellitus: A Case-Control Study.” Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2026). PMID: 41984745 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [137]
Harada K, Okazaki Y, Ichiba T. “Prehospital identification of hypoglycemia-induced seizure using a smartphone-linked continuous glucose monitoring application.” The American journal of emergency medicine (2026). PMID: 42119276 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [138]
Jiang Y, Cui Y, Su D et al.. “Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42058780 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [139]
Wherrett DK, Bundy B, Becker DJ et al.. “Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.” Lancet (London, England) (2011). PMID: 21714999 ↗
L1RCTCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [140]
Shao W, Yang K, Lu D et al.. “Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39986331 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification - [141]
Antonoglou G, Knuuttila M, Niemelä O et al.. “Serum 1,25(OH)D level increases after elimination of periodontal inflammation in T1DM subjects.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23940127 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification - [142]
Mistry S, Gouripeddi R, Raman V et al.. “Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering.” Diabetologia (2022). PMID: 36446887 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [143]
Liu GC, Fang F, Zhou J et al.. “Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse.” Diabetologia (2012). PMID: 22653270 ↗
L5OTHERCited in: Severity, Staging and Risk Stratification - [144]
Broe R, Rasmussen ML, Frydkjaer-Olsen U et al.. “Retinal vascular fractals predict long-term microvascular complications in type 1 diabetes mellitus: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).” Diabetologia (2014). PMID: 24981770 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification - [145]
Yılmaz UC, Kızılay DÖ, Kurt ÖK et al.. “Autoantibody screening in children who are first-degree relatives of individuals with type 1 diabetes in a sibling-dominant cohort in Turkey: a multicentre study on prevalence, determinants and post-screening parent-child anxiety.” Diabetologia (2026). PMID: 42350669 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [146]
Idrees H, Memon F, Alam R et al.. “Systematic Review and Meta-Analysis of Insulin Dose and Route of Administration Regimens for Diabetic Ketoacidosis in Children and Adolescents.” Journal of clinical medicine (2025). PMID: 41227190 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [147]
Fullerton B, Siebenhofer A, Jeitler K et al.. “Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2016). PMID: 27362975 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [148]
Fullerton B, Jeitler K, Seitz M et al.. “Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2014). PMID: 24526393 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [149]
Zhang Q, Saad SH, Zhou H et al.. “Development and validation of an interpretable machine learning model for predicting in-hospital hypoglycemia in adults with type 1 diabetes mellitus: a multicenter retrospective study.” Frontiers in endocrinology (2026). PMID: 42095183 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification - [150]
Wang S, Zhang Y, Balati A et al.. “Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39812177 ↗
L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [151]
Cherney DZ, Reich HN, Scholey JW et al.. “The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes.” Diabetologia (2013). PMID: 23893332 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies - [152]
Marzuillo P, Iafusco D, Zanfardino A et al.. “Acute Kidney Injury and Renal Tubular Damage in Children With Type 1 Diabetes Mellitus Onset.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33595665 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [153]
Dugan CW, Maloney SK, Abramoff KJ et al.. “Effects of Simulated High Altitude on Blood Glucose Levels During Exercise in Individuals With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34935935 ↗
L1OTHERCited in: Acute Management and Endocrine Emergencies - [154]
Owens LA, Avalos G, Kirwan B et al.. “ATLANTIC DIP: closing the loop: a change in clinical practice can improve outcomes for women with pregestational diabetes.” Diabetes care (2012). PMID: 22826448 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [155]
Goedendorp MM, Tack CJ, Steggink E et al.. “Chronic fatigue in type 1 diabetes: highly prevalent but not explained by hyperglycemia or glucose variability.” Diabetes care (2013). PMID: 23949561 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies - [156]
Tsujimoto T, Yamamoto-Honda R, Kajio H et al.. “Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.” Diabetes care (2013). PMID: 23939540 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [157]
Chantzichristos D, Eliasson B, Johannsson G. “MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32299062 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [158]
Barchetta I, Alessandri C, Bertoccini L et al.. “Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.” European journal of endocrinology (2015). PMID: 26578639 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [159]
Ishida-Oku M, Iwase M, Sugitani A et al.. “A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor.” Diabetologia (2009). PMID: 19911164 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [160]
Assogba FG, Couchoud C, Hannedouche T et al.. “Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011.” Diabetologia (2014). PMID: 24496924 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [161]
Beulens JW, Kruidhof JS, Grobbee DE et al.. “Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study.” Diabetologia (2008). PMID: 18626626 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [162]
Gomes JAF, Vasconcelos AR, Nascimento Júnior JRAD et al.. “Perceived Exertion Is Associated with Cardiovascular Strain but Not Glycemic Response to Gym-Based Exercise in Adults with Type 1 Diabetes: An Exploratory Randomized Crossover Trial.” International journal of environmental research and public health (2026). PMID: 42354343 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [163]
Mitchell S, Patwardhan K, Lucocq J et al.. “Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: A comprehensive updated systematic review and meta-analysis.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41904365 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies - [164]
Guo Y, Mei Y, Bongaerts B et al.. “(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.” The Cochrane database of systematic reviews (2026). PMID: 42318853 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies - [165]
Skott E, Cai W, Stiernborg M et al.. “Associations of prenatal exposure to maternal autoimmune disorders with a wide spectrum of psychiatric and neurodevelopmental disorders in offspring-a nationwide cohort study.” Human reproduction open (2026). PMID: 42077501 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [166]
Kim JY, Kim S, Kim JH. “Association between Continuous Glucose Monitoring and Risk of Acute Diabetes-Related Complications in Pediatric Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2026). PMID: 42014052 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [167]
Kang YM, Giugliano RP, Ran X et al.. “Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.” Diabetes care (2025). PMID: 40544474 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [168]
Ruiz de Adana MS, Alhambra-Expósito MR, Muñoz-Garach A et al.. “Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.” Diabetes care (2019). PMID: 31831473 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [169]
Porcellati F, Lucidi P, Candeloro P et al.. “Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.” Diabetes care (2018). PMID: 30305345 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [170]
Rys PM, Ludwig-Slomczynska AH, Cyganek K et al.. “Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies.” European journal of endocrinology (2018). PMID: 29545258 ↗
L1SR_MA_RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [171]
Ocheltree SM, Hompesch M, Wondmagegnehu ET et al.. “Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.” European journal of endocrinology (2010). PMID: 20508081 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [172]
Del Favero S, Bruttomesso D, Di Palma F et al.. “First use of model predictive control in outpatient wearable artificial pancreas.” Diabetes care (2014). PMID: 24757228 ↗
L4TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [173]
Park J, Ntelis S, Yunasan E et al.. “Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37561012 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [174]
Bergenstal RM, Tamborlane WV, Ahmann A et al.. “Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.” The New England journal of medicine (2010). PMID: 20587585 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [175]
Russell SJ, El-Khatib FH, Sinha M et al.. “Outpatient glycemic control with a bionic pancreas in type 1 diabetes.” The New England journal of medicine (2014). PMID: 24931572 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [176]
Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al.. “Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.” The New England journal of medicine (2009). PMID: 19940299 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [177]
Osipova J, Fischer DC, Dangwal S et al.. “Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24937532 ↗
L4COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [178]
Heller S, Buse J, Fisher M et al.. “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.” Lancet (London, England) (2012). PMID: 22521071 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [179]
Beam CA, MacCallum C, Herold KC et al.. “GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.” Diabetologia (2016). PMID: 27704166 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [180]
Thorius IH, Husemoen LLN, Nordsborg RB et al.. “Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.” Diabetologia (2023). PMID: 36640191 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [181]
Al-Naseem AO, Attia A, Gonnah AR et al.. “Pancreas transplantation today: quo vadis?” European journal of endocrinology (2023). PMID: 36929837 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [182]
Wiegand S, Raile K, Reinehr T et al.. “Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy.” European journal of endocrinology (2008). PMID: 18362302 ↗
L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [183]
Moser O, Becker U, van den Boom L et al.. “[Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].” Wiener klinische Wochenschrift (2026). PMID: 42162485 ↗
L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [184]
Amaral R, Costa B, Penedones A et al.. “Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials.” Diabetes, obesity & metabolism (2026). PMID: 42225295 ↗
L1TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [185]
Bellin MD, Dunn TB. “Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies.” Diabetologia (2020). PMID: 32894315 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [186]
Tamahane V, Shah N, Kajale N et al.. “Effect of prebiotic intervention on glycemic control and gut microbiome profile in Indian children with type 1 diabetes mellitus (T1DM): a pilot randomised control trial.” Endocrine (2026). PMID: 42165942 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [187]
Campbell F, Biggs K, Aldiss SK et al.. “Transition of care for adolescents from paediatric services to adult health services.” The Cochrane database of systematic reviews (2016). PMID: 27128768 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [188]
Abdelghaffar S, Attia AM. “Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.” The Cochrane database of systematic reviews (2009). PMID: 19160294 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [189]
Hemmingsen B, Metzendorf MI, Richter B. “(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2021). PMID: 33662147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [190]
Vardi M, Jacobson E, Nini A et al.. “Intermediate acting versus long acting insulin for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2008). PMID: 18646147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [191]
Misso ML, Egberts KJ, Page M et al.. “Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2010). PMID: 20091571 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [192]
Copur S, Mizrak B, Ozbek L et al.. “Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.” Medeniyet medical journal (2026). PMID: 42383405 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [193]
Toghi-Eshghi SR, Yardley JE. “Morning (Fasting) vs Afternoon Resistance Exercise in Individuals With Type 1 Diabetes: A Randomized Crossover Study.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31211392 ↗
L1RCTCited in: History and Evolution of Treatment - [194]
Parthasarathy G, Kudva YC, Low PA et al.. “Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial.” The Journal of clinical endocrinology and metabolism (2017). PMID: 27880079 ↗
L1RCTCited in: History and Evolution of Treatment - [195]
Haider DG, Pleiner J, Francesconi M et al.. “Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16895956 ↗
L4RCTCited in: History and Evolution of Treatment - [196]
Sarem Z, Bumke-Vogt C, Mahmoud AM et al.. “Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28911141 ↗
L1RCTCited in: History and Evolution of Treatment - [197]
Crowne EC, Samra JS, Cheetham T et al.. “The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2001). PMID: 11502796 ↗
L1RCTCited in: History and Evolution of Treatment - [198]
Griffen SC, Oostema K, Stanhope KL et al.. “Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2005). PMID: 16317063 ↗
L1RCTCited in: History and Evolution of Treatment - [199]
Herold KC, Hagopian W, Auger JA et al.. “Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037148 ↗
L1RCTCited in: History and Evolution of Treatment - [200]
. “Effects of insulin in relatives of patients with type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037147 ↗
L1RCTCited in: History and Evolution of Treatment - [201]
Nathan DM, Lachin J, Cleary P et al.. “Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.” The New England journal of medicine (2003). PMID: 12788993 ↗
L2RCTCited in: History and Evolution of Treatment - [202]
Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.. “Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.” The New England journal of medicine (2005). PMID: 15972866 ↗
L1RCTCited in: History and Evolution of Treatment - [203]
Skyler JS, Cefalu WT, Kourides IA et al.. “Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study.” Lancet (London, England) (2001). PMID: 11210993 ↗
L1RCTCited in: History and Evolution of Treatment - [204]
Shapiro AM, Lakey JR, Ryan EA et al.. “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.” The New England journal of medicine (2000). PMID: 10911004 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [205]
Bally L, Zueger T, Buehler T et al.. “Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study.” Diabetologia (2016). PMID: 26739816 ↗
L1RCTCited in: History and Evolution of Treatment - [206]
Ang M, Meyer C, Brendel MD et al.. “Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes.” Diabetologia (2013). PMID: 24305963 ↗
L3RCTCited in: History and Evolution of Treatment - [207]
Garg S, Rosenstock J, Silverman BL et al.. “Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.” Diabetologia (2006). PMID: 16506054 ↗
L1RCTCited in: History and Evolution of Treatment - [208]
Davison GW, Ashton T, George L et al.. “Molecular detection of exercise-induced free radicals following ascorbate prophylaxis in type 1 diabetes mellitus: a randomised controlled trial.” Diabetologia (2008). PMID: 18769906 ↗
L1RCTCited in: History and Evolution of Treatment - [209]
Jenni S, Oetliker C, Allemann S et al.. “Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type 1 diabetes mellitus--a prospective single-blinded randomised crossover trial.” Diabetologia (2008). PMID: 18512043 ↗
L1RCTCited in: History and Evolution of Treatment - [210]
Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S et al.. “Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.” Lancet (London, England) (2001). PMID: 11418149 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [211]
Edwards K, Li X, Lingvay I. “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36268825 ↗
L4OTHERCited in: History and Evolution of Treatment - [212]
Galassetti P, Tate D, Neill RA et al.. “Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2002). PMID: 12414885 ↗
L4OTHERCited in: History and Evolution of Treatment - [213]
Kudva YC, Reynolds C, O'Brien T et al.. “"Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes.” Diabetes care (2002). PMID: 11772912 ↗
L3OTHERCited in: History and Evolution of Treatment - [214]
Lu CL, Shen HN, Hu SC et al.. “A Population-Based Study of All-Cause Mortality and Cardiovascular Disease in Association With Prior History of Hypoglycemia Among Patients With Type 1 Diabetes.” Diabetes care (2016). PMID: 27385329 ↗
L3OTHERCited in: History and Evolution of Treatment, Complications and Long-term Sequelae - [215]
Cabrera SM, Chen YG, Hagopian WA et al.. “Blood-based signatures in type 1 diabetes.” Diabetologia (2015). PMID: 26699650 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [216]
Zhang Q, Zhou H, Lin R et al.. “Risk factors for hypoglycaemia in adults with type 1 diabetes: a systematic review and meta-analysis.” BMC endocrine disorders (2025). PMID: 41449374 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [217]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [218]
Tang D, Gao X, Zhu M et al.. “Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.” Clinical pharmacokinetics (2026). PMID: 41489799 ↗
L4RCTCited in: History and Evolution of Treatment - [219]
Drai R, Galstyan G, Karonova T et al.. “Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.” Diabetes, obesity & metabolism (2025). PMID: 41366610 ↗
L1RCTCited in: History and Evolution of Treatment - [220]
Almutairi MNASF. “Neurodevelopmental effects of severe hypoglycemia in children with type 1 diabetes: a systematic review.” Frontiers in pediatrics (2026). PMID: 41660395 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [221]
Aoki TT, Benbarka MM, Okimura MC et al.. “Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.” Lancet (London, England) (1993). PMID: 8102666 ↗
L4OTHERCited in: History and Evolution of Treatment - [222]
Kugathasan L, Katz A, Muskiet MHA et al.. “Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.” Kidney international reports (2026). PMID: 42205183 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [223]
Pham-Dobor G, Kaltenecker P, Temesfoi V et al.. “Systematic Analysis and Network Mapping of Disease Associations in Autoimmune Polyglandular Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39378147 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [224]
Łebkowska A, Adamska A, Krentowska A et al.. “The Influence of Prepubertal Onset of Type 1 Diabetes and Age of Menarche on Polycystic Ovary Syndrome Diagnosis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33537700 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [225]
van Dijk M, Donga E, van Dijk JG et al.. “Disturbed subjective sleep characteristics in adult patients with long-standing type 1 diabetes mellitus.” Diabetologia (2011). PMID: 21573904 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [226]
Xiao YL, Jia YQ, Gu LQ et al.. “Prevalence of Celiac Disease in China Among High-Risk Populations: A Systematic Review and Meta-Analysis.” Journal of digestive diseases (2025). PMID: 41183986 ↗
L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [227]
Fagerholm E, Ahlqvist E, Forsblom C et al.. “SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes.” Diabetologia (2012). PMID: 22643932 ↗
L3SR_OBSCited in: Complications and Long-term Sequelae - [228]
González-Clemente JM, Vilardell C, Broch M et al.. “Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes.” European journal of endocrinology (2007). PMID: 17609399 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [229]
Głowińska-Olszewska B, Moniuszko M, Hryniewicz A et al.. “Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients.” European journal of endocrinology (2013). PMID: 23111589 ↗
L3OTHERCited in: Complications and Long-term Sequelae - [230]
Nathan DM. “Realising the long-term promise of insulin therapy: the DCCT/EDIC study.” Diabetologia (2021). PMID: 33550441 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [231]
Chimen M, Kennedy A, Nirantharakumar K et al.. “What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review.” Diabetologia (2011). PMID: 22189486 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [232]
Colombo M, McGurnaghan SJ, Bell S et al.. “Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus.” Diabetologia (2019). PMID: 31807796 ↗
L2OTHERCited in: Complications and Long-term Sequelae - [233]
Cakmak Demir S, Batman A, Yazici D et al.. “Association of High-Risk Obstructive Sleep Apnea with Microvascular Complications in Adults with Type 1 Diabetes Mellitus: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42074704 ↗
L3CASE_CONTROLCited in: Complications and Long-term Sequelae - [234]
Rodrigues F, White M, O'Connell MA. “Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42387672 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [235]
Tentolouris A, Popovic DS, Liarakos AL et al.. “GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.” Diabetes, obesity & metabolism (2026). PMID: 42380553 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [236]
García-Poblet M, Martínez-Sanz JM, Alberola-Chazarra MA et al.. “Phase angle and triglyceride-glucose index as biomarkers of glycemic control, body composition and cardiovascular risk in adolescents with type 1 diabetes: a cross-sectional study.” Journal of endocrinological investigation (2026). PMID: 42371339 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [237]
Buschur EO, Polsky S. “Type 1 Diabetes: Management in Women From Preconception to Postpartum.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33331893 ↗
L5SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [238]
Basu A, Alaupovic P, Wu M et al.. “Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22438226 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [239]
Kim KM, Kim KJ, Han K et al.. “Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37850407 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [240]
Castellaneta S, Piccinno E, Oliva M et al.. “High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.” Diabetes care (2015). PMID: 25784659 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [241]
Allen LA, Cannings-John RL, Evans A et al.. “Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population-based e-cohort study.” Diabetologia (2019). PMID: 31863141 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [242]
Tosur M, Geyer SM, Rodriguez H et al.. “Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.” Diabetologia (2018). PMID: 29931415 ↗
L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [243]
García-Patterson A, Gich I, Amini SB et al.. “Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction.” Diabetologia (2009). PMID: 20013109 ↗
L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [244]
Alshehri MS, Alsadoon A, Albazei A et al.. “Pars plana vitrectomy for tractional and combined tractional rhegmatogenous retinal detachment in type 1 diabetes mellitus: outcomes, prognostic factors, and a proposed staging system.” International journal of retina and vitreous (2026). PMID: 42087261 ↗
L2bCited in: Definition, Classification and Axis Nomenclature - [245]
Maciulewski R, Buczyńska-Backiel A, Zielińska-Maciulewska A et al.. “Baseline β-Cell Secretory Reserve and Its Association with Glycaemic Control and Long-Term Outcomes Across Diabetes Phenotypes.” International journal of molecular sciences (2026). PMID: 41752170 ↗
L2bCited in: Definition, Classification and Axis Nomenclature - [246]
İnözü M, Yaşartekin Y, Buluş AD et al.. “Serum uric acid level as a marker associated with microalbuminuria in pediatric patients with type 1 diabetes mellitus.” European journal of pediatrics (2025). PMID: 41329208 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [247]
Abdulla S, Alemadi B, Bin Shafar L et al.. “Prevalence of hypothyroidism among patients undergoing thyroid function tests in primary healthcare centres in Dubai, UAE.” BMC public health (2025). PMID: 40999380 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [248]
Tang N, Su N, Zhang Z et al.. “Retinal vessel metric analysis of type 1 diabetes mellitus in OCT angiography.” Frontiers in medicine (2025). PMID: 40584707 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [249]
Di Giacomo R, Gasparini V, Salvucci G et al.. “Autoimmune polyglandular syndrome and GAD65 related-temporal lobe epilepsy.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40571861 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [250]
Bampton TJ, Chen JW, Brown A et al.. “Epidemiology and burden of adult chronic pancreatitis in South Australia: a 20-year data linkage study.” BMJ open (2025). PMID: 40050052 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [251]
Xian J, Du R, Yuan H et al.. “The application of predictive value of diabetes autoantibody profile combined with clinical data and routine laboratory indexes in the classification of diabetes mellitus.” Frontiers in endocrinology (2024). PMID: 39247917 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [252]
Tas N, Mengen E, Alacakır N et al.. “Is there a relationship between hyperchloremia status and the risk of developing acute kidney injury in pediatric patients with diabetic ketoacidosis?” European journal of pediatrics (2024). PMID: 39080001 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [253]
Eken B, Rawshani A, Rawshani A et al.. “Effects of pre-existing type 1 diabetes mellitus on survival outcome following out-of-hospital cardiac arrest: a registry-based observational study in Sweden.” BMJ open (2024). PMID: 39009457 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [254]
Huang X, Ouyang D, Xie W et al.. “Development and validation of machine learning-based diagnostic models using blood transcriptomics for early childhood diabetes prediction.” Frontiers in medicine (2025). PMID: 40740938 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [255]
He X, Wang X, van Heck J et al.. “Blood immune cell profiling in adults with longstanding type 1 diabetes is associated with macrovascular complications.” Frontiers in immunology (2024). PMID: 39011037 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [256]
Casadei G, Baldari M, Brognara L et al.. “Plantar fascia thickness in type 1 diabetes mellitus patients: Clinical associations and metabolic correlates.” Journal of diabetes investigation (2026). PMID: 42046319 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [257]
Gómez-Coronado-Martín R, Salinero-Fort MÁ, López-de-Andrés A et al.. “Clinical Validation of Type 1 Diabetes Coding in Hospital Discharge Records Using ADA Criteria: Implications for Spanish and European Health Data Spaces.” Journal of clinical medicine (2026). PMID: 41899210 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [258]
Bayona Cebada A, Nattero-Chávez L, De la Calle De la Villa E et al.. “Androgen excess disorders remain undiagnosed in one of every four premenopausal women with Type 1 diabetes.” Human reproduction open (2025). PMID: 40747135 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [259]
Yang D, Yang L, Yang J et al.. “Beyond the known: prospective research directions for the gut-brain axis in obesity and type 1 diabetes mellitus.” Diabetology & metabolic syndrome (2026). PMID: 42050719 ↗
L2bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [260]
Chen D, Zhang F, Ren T et al.. “Alterations of sphingosine-1-phosphate and its receptors in type 1 diabetes mellitus: an integrated clinical and single-cell transcriptomic study.” Frontiers in immunology (2026). PMID: 42338584 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [261]
Olson TE, Lloyd TS, Hamad CD et al.. “Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.” JOR spine (2026). PMID: 42253285 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [262]
Min H, Li J, Wang J et al.. “Lipidomic signatures associated with cognitive impairment in type 1 diabetes mellitus: a pilot study integrating clinical serum and mouse hippocampus.” Journal of translational medicine (2026). PMID: 42157048 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [263]
Gómez-Barba JM, Cañete-Massé C, Gallardo-Moreno GB et al.. “Machine learning and regional homogeneity reveal early and subtle brain changes in type 1 diabetes.” Journal of neuroradiology = Journal de neuroradiologie (2026). PMID: 42119663 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [264]
Golodnikov II, Podshivalova ES, Chechekhin VI et al.. “Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes.” JCI insight (2025). PMID: 41325163 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [265]
Mohamed Ali Elbashir R, Elbashir A, Urimuke Basake R et al.. “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.” Cureus (2025). PMID: 41341350 ↗
L1aCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [266]
Marzban M, Ahmadi N, Sotoodehnejadnematalahi F et al.. “Design and application of a multi-epitope ACE2 antigen for detection of autoantibodies in post-COVID-19 diagnosed type 1 diabetes.” Immunology letters (2025). PMID: 41478466 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [267]
Alaei-Shahmiri F, Ghafoury R, Rimaz S et al.. “Attitudes toward Mobile App Use in Individuals with Type 1 Diabetes Mellitus: A Quasi-Experimental Mixed-Methods Investigation of a Digital Support Tool for Diabetes Self-Management Behavior.” Medical journal of the Islamic Republic of Iran (2026). PMID: 42516649 ↗
L2bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [268]
Fantasia KL, Lanzinger S, Rompicherla S et al.. “Missed opportunities for risk reduction: type 1 diabetes management in older adults in DPV and T1DX-QI registries.” Journal of the Endocrine Society (2026). PMID: 41728214 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [269]
Hu Z, Zhu M, Tang L et al.. “Population Pharmacokinetic/Pharmacodynamic Modeling of Volagidemab, a Glucagon Receptor Antagonist, in Healthy Chinese and US Subjects Following Single Subcutaneous Administration.” Pharmaceutical research (2026). PMID: 41714547 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [270]
van Rhijn RI, van Trotsenburg ASP, Mentink R. “Autoantibody-Positive versus Autoantibody-Negative Type 1 Diabetes in Children: Clinical and Biochemical Characteristics.” Hormone research in paediatrics (2026). PMID: 41774599 ↗
L3bCited in: Clinical Presentation - [271]
Muzslay E, Herczeg V, Pusztai RI et al.. “Overweight worsens the metabolic presentation of type 1 diabetes mellitus in children.” Frontiers in endocrinology (2026). PMID: 41585812 ↗
L3bCited in: Clinical Presentation - [272]
Linck JA, Michels C, Schwanstecher A et al.. “Current Clinical Features of Diabetic Ketoacidosis in Adults: A German Multicenter Study 2022-2023.” Diabetes technology & therapeutics (2026). PMID: 41005769 ↗
L4Cited in: Clinical Presentation - [273]
Taneri PE, Bongaerts B, Shokraee K et al.. “Timing, frequency, and glycaemic target values for self-monitoring in adults with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2026). PMID: 42559751 ↗
L1aCited in: Clinical Presentation - [274]
Fu R, Yang M, Guo Y et al.. “Case Report: Case analysis of a juvenile type 1 diabetes mellitus patient with Mauriac syndrome.” Frontiers in endocrinology (2026). PMID: 42528668 ↗
L4Cited in: Clinical Presentation - [275]
Chung JS, Kim JS, Ju JK. “Surgical abdomen masked by metabolic crisis: fulminant ischemic colitis in severe diabetic ketoacidosis - a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42516746 ↗
L5Cited in: Clinical Presentation - [276]
Jin F, Wu W, Yang X et al.. “Dendritic Cells as Immunometabolic Regulatory Nodes in Diabetes: Molecular Mechanisms and Therapeutic Reprogramming.” International journal of molecular sciences (2026). PMID: 42450322 ↗
L5Cited in: Clinical Presentation - [277]
Kouhanjani MF, Plautz A, Melzer N et al.. “Autoimmune encephalitis-associated epilepsy with glutamic acid decarboxylase autoantibodies and type 1 diabetes mellitus: A comprehensive systematic scoping review of a clinical syndrome.” Autoimmunity reviews (2026). PMID: 42173229 ↗
L5Cited in: Clinical Presentation - [278]
Ilmer S, Sohail R, Hyman S. “25-hydroxyvitamin D and the initial presentation of pediatric type 1 diabetes: associations with ketoacidosis severity and beta-cell function.” Frontiers in endocrinology (2026). PMID: 42169725 ↗
L5Cited in: Clinical Presentation - [279]
Shore B. “Editorial Commentary: Outcomes and Complication Risk in Type 1 Diabetic Patients Undergoing Hip Arthroscopy-Diabetes is NOT a Single Disease.” Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association (2026). PMID: 41995260 ↗
L5Cited in: Clinical Presentation - [280]
Almallouhi A, Sadek M, Absah I. “Clinical outcome of constipation as the presenting symptom in children with celiac disease.” Journal of pediatric gastroenterology and nutrition (2025). PMID: 41431920 ↗
L5Cited in: Clinical Presentation - [281]
Kahkoska AR, Neumiller JJ, Alexopoulos AS et al.. “Preparing to Meet the Needs of a Growing Older Adult Population with Type 1 Diabetes: A Narrative Review.” Journal of general internal medicine (2025). PMID: 41361045 ↗
L5Cited in: Clinical Presentation - [282]
Kwon S, Kim BS, Han K et al.. “Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis: A Nationwide Cohort Study in South Korea.” Neurology (2026). PMID: 42555884 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [283]
Okuma H, Tsutsumi T, Ichijo M et al.. “Serum-derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus.” Journal of diabetes investigation (2026). PMID: 42549632 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [284]
Yaman Ortakoylu M, Gonc EN, Ozon A et al.. “Frequency of autoimmune diseases in children and adolescents with type 1 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42445886 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [285]
Astavans A, Baughman D, Mathioudakis N. “Long-Term Major Adverse Cardiovascular and Cerebrovascular Event Risk in Adult-Onset Type 1 Versus Type 2 Diabetes: A Propensity-Matched Cohort Study.” European journal of preventive cardiology (2026). PMID: 42429688 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [286]
Altıntop SE, Barlas T, Kılıc ACK et al.. “Liver fibrosis risk: a silent threat in type 1 diabetes mellitus.” Journal of endocrinological investigation (2026). PMID: 42566182 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [287]
Fang H, Yin J, Tian S et al.. “Thalamic Nuclei Atrophy in Type 1 Diabetes Mellitus Across Disease Duration.” Journal of magnetic resonance imaging : JMRI (2026). PMID: 42312577 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [288]
Aboelenin HM, ElTaher H, Elzehery R et al.. “Evaluation of FABP1 as a biomarker of diabetic kidney disease in children with type 1 diabetes.” European journal of pediatrics (2026). PMID: 42298045 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [289]
Styles SE, Haszard JJ, Oravcova-Wheeler Z et al.. “Preliminary Outcomes of a Brief Values-Guided Self-Management Intervention to Improve Glucose Levels Among Emerging Adults With Type 1 Diabetes and Above-Recommended HbA1c: A Pilot Study.” Endocrinology, diabetes & metabolism (2026). PMID: 42234497 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [290]
Mesa Díaz ÁM, Rodríguez de Vera Gómez P, Ruiz Rodríguez M et al.. “Clinical and socioeconomic determinants of glycaemic control derived from continuous glucose monitoring in adults with type 1 diabetes.” Frontiers in endocrinology (2026). PMID: 42109724 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [291]
Zheng R, Zhang C, Sun X et al.. “Time in tight range and time in range in relation to diabetic retinopathy and OCTA-derived retinal microvascular parameters in hospitalized adults with type 1 diabetes.” Endocrine (2026). PMID: 42545593 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [292]
Boca LO, Ghiga G, Păduraru G et al.. “Pediatric celiac disease and coexisting immune-mediated conditions: a five-year single-center study from North-Eastern Romania.” Frontiers in pediatrics (2026). PMID: 42317660 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [293]
Tang J, Hou Q, Ye J et al.. “Case Report: A diabetic ketoacidosis in adolescents complicated with rhino-orbital-cerebral mucormycosis.” Frontiers in medicine (2026). PMID: 42524461 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [294]
Hsu JC, Lo FS, Jeng JS et al.. “Association of low-grade albuminuria and triple-line pattern as markers of early peripheral vascular remodeling in adolescents with type 1 diabetes.” Journal of diabetes investigation (2026). PMID: 41804023 ↗
L2bCited in: Severity, Staging and Risk Stratification - [295]
Croce L, Gatta E, Gallo M et al.. “Thyroid eye disease in the context of autoimmune polyglandular syndromes: comparative clinical insights from a retrospective study.” Frontiers in endocrinology (2026). PMID: 42568487 ↗
L4Cited in: Severity, Staging and Risk Stratification - [296]
Xiang J, Gao W, Yao Y et al.. “Association between triglyceride-glucose index and diabetic kidney disease in adults with type 1 diabetes.” BMC endocrine disorders (2026). PMID: 41965604 ↗
L3bCited in: Severity, Staging and Risk Stratification - [297]
Bogusz-Górna K, Polańska A, Dańczak-Pazdrowska A et al.. “Selected parameters of epidermal barrier in juveniles with type 1 diabetes correspond with the severity of diabetes - an observational study.” Frontiers in endocrinology (2025). PMID: 41377944 ↗
L3bCited in: Severity, Staging and Risk Stratification - [298]
Abdullah MY, Laaribi AB, Babay W et al.. “Cytokine profiles, genetic polymorphisms, and systemic inflammatory markers in type 1 diabetes patients with COVID-19: IL-18 a predictor of disease severity.” Frontiers in immunology (2026). PMID: 41846929 ↗
L3bCited in: Severity, Staging and Risk Stratification - [299]
Taskin Kursun S, Imre E, Gogas Yavuz D. “Advanced glycation end-products and sclerostin are elevated across diabetes phenotypes and associated with vertebral fractures in type 2 diabetes.” BMC endocrine disorders (2026). PMID: 41963900 ↗
L3bCited in: Severity, Staging and Risk Stratification - [300]
Chakraborty P, Basu M, Mukhopadhyay P et al.. “Study of oral microbiome by next generation sequencing in T1DM adolescents with periodontal disease.” Acta diabetologica (2026). PMID: 41661275 ↗
L3bCited in: Severity, Staging and Risk Stratification - [301]
Ma D, Xu W, Yang Y et al.. “Efficacy and Safety of Open-Source Hybrid Closed-Loop Automated Insulin Delivery in Perioperative Patients.” Biomedicines (2026). PMID: 42193423 ↗
L1bCited in: Acute Management and Endocrine Emergencies - [302]
Chen H, Lin Z, Liu Z et al.. “Effect of sodium-glucose cotransporter-2 inhibitors on fracture risk in patients with type 1 diabetes receiving insulin-based therapy: a meta-analysis.” PeerJ (2026). PMID: 42011364 ↗
L1aCited in: Acute Management and Endocrine Emergencies - [303]
Alharbi TH, Alzahrani HA, Alromaihi RA et al.. “Immune checkpoint inhibitor-induced type 1 diabetes mellitus: incidence, risk factors, and prognostic implications - a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42456777 ↗
L2aCited in: Acute Management and Endocrine Emergencies - [304]
Ramos Cardona JC, Morecroft R, Martinez S et al.. “Glycemic variability associated with gamma secretase inhibitor therapy in a type 1 diabetic patient undergoing treatment for desmoid tumor: a case report.” Frontiers in endocrinology (2026). PMID: 42147100 ↗
L2bCited in: Acute Management and Endocrine Emergencies - [305]
Montes FR, Gutierrez-Navarro JD, Restrepo-Patiño N et al.. “Perioperative outcomes and phase-specific intraoperative glycemic management in simultaneous pancreas-kidney transplantation: A single-center case series.” World journal of transplantation (2026). PMID: 42281876 ↗
L4Cited in: Acute Management and Endocrine Emergencies - [306]
Vayser D, Wang P, Dafesh N et al.. “Outcomes of Diabetes Management with Continuous Glucose Monitoring Technology.” Archives of internal medicine research (2026). PMID: 42306173 ↗
L1bCited in: Acute Management and Endocrine Emergencies - [307]
Juhi A, Kumari R, Mondal H et al.. “Objective Sleep and Circadian Metrics in Adolescents With Type 1 Diabetes Mellitus: A Systematic Review.” Journal of diabetes science and technology (2026). PMID: 42449541 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [308]
Yadav J, Kumar J, Kumar R et al.. “Efficacy and safety of stem cell therapy in type 1 diabetes: A systematic review and meta-analysis of randomised controlled trials.” The Indian journal of medical research (2026). PMID: 42397823 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [309]
Reguram R, Shah R, Vora T et al.. “Insulin Pump Use and Hospital Outcomes in Adults With Type 1 Diabetes: A 2022 Nationwide Readmissions Database Analysis.” The Journal of clinical endocrinology and metabolism (2026). PMID: 42530032 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [310]
Cyranka K, Klupa T, Matejko B et al.. “Exploring key targets for psychodiabetological interventions in adults with type 1 diabetes mellitus: an exploratory network and intervention modeling study using Polish MyDiaMate data.” Diabetes research and clinical practice (2026). PMID: 42480716 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [311]
de Lope Quiñones S, Luque-Ramírez M, Quintero Tobar A et al.. “Metabolomic signatures of glycemic control in type 1 diabetes: insights from continuous glucose monitoring.” Journal of endocrinological investigation (2026). PMID: 42474688 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [312]
Shamsnia HS, Peyrovinasab A, Niknejad A et al.. “BCG vaccination as an adjunctive strategy in type 1 diabetes: A systematic review of immunometabolic effects and clinical evidence.” Pathology, research and practice (2026). PMID: 42361719 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [313]
Lü Y, Li Z, Yang Y et al.. “Insulin pump therapy for T1D: a real-world analysis of a novel two-in-one insulin pump in Chinese adults with type 1 diabetes.” Diabetology & metabolic syndrome (2026). PMID: 42332795 ↗
L4Cited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [314]
Gómez AM, Henao-Carrillo D, Muñoz-Velandia O et al.. “Virtual vs. In-Person Training for MinMed™ 780G Initiation: Comparable Effectiveness and Safety in Adults with Type 1 Diabetes.” Clinical medicine insights. Endocrinology and diabetes (2026). PMID: 42482835 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [315]
Cheng Y, Gaborcik JW, Smith RM et al.. “Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis.” The Annals of pharmacotherapy (2026). PMID: 42421396 ↗
L4Cited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [316]
Emilia KK, Magdalena D, Lidia G et al.. “Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41968383 ↗
L1bCited in: History and Evolution of Treatment - [317]
Lee HS, Kim HY, Yang M et al.. “Familial Occurrence of Type 1 Diabetes Mellitus in Korean Children and Adolescents: A Multicenter Study.” Diabetes & metabolism journal (2026). PMID: 41782396 ↗
L3bCited in: History and Evolution of Treatment - [318]
Chen L, Yan C, Huang C et al.. “Upregulation of ADAM19 in dendritic cells is associated with immune features and lower C-peptide levels in type 1 diabetes mellitus.” Diabetology & metabolic syndrome (2026). PMID: 42249412 ↗
L3bCited in: History and Evolution of Treatment - [319]
González-Garrido AA, Gallardo-Moreno GB, Gómez-Barba JM et al.. “Changes in Brain Volumetric Measures Associated With Type 1 Diabetes Depict an Evolutionary Adaptation Process to Developmental Cognitive Demands.” Diabetes/metabolism research and reviews (2026). PMID: 41994900 ↗
L3bCited in: History and Evolution of Treatment - [320]
Rodríguez de Vera Gómez P, Bellido V, Damas Fuentes M et al.. “Development and Validation of Nomogram-Based Predictive Models for Severe Hypoglycemia in Adults With Type 1 Diabetes Treated With Multiple Daily Injections: The SEHYPAN Study.” Diabetes/metabolism research and reviews (2026). PMID: 41791767 ↗
L3bCited in: History and Evolution of Treatment - [321]
Zhu Y, Yang H, Hu C et al.. “Thyroid autoimmunity in relation to islet autoantibodies in newly diagnosed type 1 diabetes mellitus in children and adolescents.” Frontiers in endocrinology (2026). PMID: 42181188 ↗
L3bCited in: History and Evolution of Treatment - [322]
Lipták L, Lipták K, Kempler P et al.. “Early hyperaesthesia and late hypoaesthesia as manifestations of sensory neuropathy in dentistry - two case reports.” Frontiers in endocrinology (2026). PMID: 41685245 ↗
L4Cited in: History and Evolution of Treatment - [323]
Avçin E, Açıkgöz A. “The effect of tele-nursing application on metabolic control, self-efficacy, quality of life and anxiety level in adolescents with Type 1 diabetes: A randomized controlled trial.” Journal of pediatric nursing (2026). PMID: 41653762 ↗
L1bCited in: History and Evolution of Treatment - [324]
Shahim E, Bahrololoom R, Ataollahi M et al.. “Diminished Hepatitis B Antibody Response in Pediatrics With Type 1 Diabetes; the Need for Revaccination Protocol: A Case-Control Study.” Health science reports (2026). PMID: 42528937 ↗
L3bCited in: History and Evolution of Treatment - [325]
Nourbakhsh M, Rouhani F, Razzaghy-Azar M et al.. “Interleukin-6 and Oncostatin M Levels in Patients With Type 1 Diabetes and Its Relationship With Glycemic Indices.” Endocrinology, diabetes & metabolism (2026). PMID: 41917697 ↗
L3bCited in: History and Evolution of Treatment - [326]
Robeva R, Kirilov G, Kalinov K et al.. “Autoimmune diseases in patients with different PCOS phenotypes.” Frontiers in reproductive health (2026). PMID: 42099450 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [327]
Girardi KG, Surucu S, Jonnalagadda A et al.. “Type 1 Diabetes Mellitus Correlates With Increased Postoperative Complications and Rates of Conversion to Total Hip Arthroplasty Following Hip Arthroscopy for Femoroacetabular Impingement Syndrome.” Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association (2026). PMID: 41995211 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [328]
Pellikka I, Ventelä J, Auvinen A et al.. “Association of Childhood Acute Leukemia With Autoimmune Diseases.” International journal of cancer (2026). PMID: 41981796 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [329]
Schmolly K, Rudrapatna V, Beaven S. “Recommendations for recognizing and diagnosing Acute Hepatic Porphyria in atypical patient populations.” Orphanet journal of rare diseases (2025). PMID: 41345676 ↗
L4Cited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [330]
Haqi Ismael A, Hameed EK. “Insulin resistance in type 1 diabetes: the silent burden unmasked by eGDR.” Acta diabetologica (2026). PMID: 41619053 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [331]
Attia N, Al Noaim K, Mustafa M et al.. “The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance.” Pediatric diabetes (2025). PMID: 41424588 ↗
L4Cited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [332]
Velardi V, Sanson L, Toffoli B et al.. “Under-recognition of autoimmune polyendocrine syndromes in T1DM: results from an extended screening workup.” Endocrine (2026). PMID: 42541639 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [333]
Pascual-Morena C, Garrido-Miguel M, Martínez-García I et al.. “Efficacy of Omega-3 Polyunsaturated Fatty Acid Supplementation on the Lipid and Glycemic Profile in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Nutrition reviews (2026). PMID: 42497400 ↗
L1aCited in: Complications and Long-term Sequelae - [334]
Wang Y, Liu J, Cao F et al.. “Association of healthy lifestyle with incident cardiovascular diseases in individuals with type 1 diabetes mellitus: a prospective cohort study.” Diabetology & metabolic syndrome (2026). PMID: 42443959 ↗
L2bCited in: Complications and Long-term Sequelae - [335]
Chu Y, Zhu J, Liu Z et al.. “Metabolic mediators linking type 1 diabetes mellitus to osteoporosis.” Archives of medical science : AMS (2025). PMID: 42110599 ↗
L2bCited in: Complications and Long-term Sequelae - [336]
Bonhoure A, Yardley JE, Boudreau V et al.. “Physical and psychosocial complications faced by postmenopausal women with type 1 diabetes: a cross-sectional BETTER analysis.” Diabetes research and clinical practice (2026). PMID: 42551704 ↗
L3bCited in: Complications and Long-term Sequelae - [337]
Chausheva G, Shefket S, Bocheva Y et al.. “Platelet Indices and Adipokines in Adults with Long-Standing Type 1 Diabetes.” Journal of clinical medicine (2026). PMID: 42355786 ↗
L3bCited in: Complications and Long-term Sequelae - [338]
Kietaibl AT, Säemann M, Scherr S et al.. “Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.” Therapeutic advances in endocrinology and metabolism (2026). PMID: 42491266 ↗
L4Cited in: Complications and Long-term Sequelae - [339]
Botella-Juan L, Aguilera-Buenosvinos I, Antequera-González M et al.. “Disordered Eating Behaviours and Associated Factors Among People With Type 1 Diabetes: A Cross-Sectional Study in Spain-D1ANAS Project.” Diabetes/metabolism research and reviews (2026). PMID: 42455961 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [340]
Zhou X, Yang M, Xue M et al.. “Trends in Diabetes Mellitus Burden and Changes in Attributable Risk Factors in Asia from 1990 to 2021: Results from the Global Burden of Disease Study 2021.” Endocrinology and metabolism (Seoul, Korea) (2026). PMID: 42438067 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [341]
Ozen G, Zanfardino A, Ozen Acan G et al.. “Attenuated Seasonality of Childhood Type 1 Diabetes with Increasing Autoimmune Comorbidities: A 40-year Cohort Study.” Irish journal of medical science (2026). PMID: 42484831 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [342]
Rao S, Li T, Yan Z et al.. “Association between vitamin A and D levels and the risk of type 1 diabetes mellitus in children.” Frontiers in nutrition (2026). PMID: 42358308 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [343]
Li W, Qin L, Gaohui Z et al.. “Incidence and factors associated with hypoglycemia in newly diagnosed hospitalized children and adolescents with type 1 diabetes mellitus in China.” Frontiers in clinical diabetes and healthcare (2026). PMID: 42273407 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [344]
Ramani PK, Haynie CM, Beemarajan E et al.. “GAD65 Antibody-Associated Epilepsy and Autoimmune Encephalitis in Children and Young Adults: A Single-Center Case Series and Review of Literature.” Journal of child neurology (2026). PMID: 42227208 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [345]
Chellali DA, Benakriche BM, Belbouab R et al.. “Impact of age at diagnosis of type 1 diabetes on the occurrence of celiac disease in children.” Qatar medical journal (2026). PMID: 42534737 ↗
L4Cited in: Prognosis, Natural History, Special Populations and Prevention